# SYRIA NATIONAL ACTION PLAN ON COMBATING ANTIMICROBIAL RESISTANCE

<u>This document was prepared by:</u> Dr. Rima Moghnieh, MD (WHO consultant on AMR) along with professionals and stakeholders from Syria whose names and functions are listed below (alphabetical order):

Name	Function					
Dr. Ahmad	Order of Physicians Representative					
Ghotani	Order of Physicians Representative					
Dr. Ahmad	Private laboratory, Laboratory Commission (هيئة المخابر)					
Darwish						
Dr. Amer Teebi	AMR "Awareness Axis A" focal point Head of Hepatitis Department, Ministry of Health					
Mr. Amer Yousof	Media Office, Ministry of Health					
Mrs. Asmahan Kefa	Associate Director of Health Professions, Ministry of Health					
Dr. Atef Altawel	Head of the Department of Environmental Health, Ministry of Health					
Dr. Bashar Haj Ali	AMR "Infection Prevention and Control Axis C" focal point, Head of Infection Control Department, Hospital Directorate, Ministry of Health					
Dr. Bashar Kenani	Deputy of the Director of Hospital Directorate, Ministry of Health					
Dr. Eyad Qatraji	Private laboratory, Laboratory Commission (هيئة المخابر)					
Dr. Fatima	AMR "Surveillance Axis B" focal point,					
Mansour	Public Health Laboratories, Ministry of Health					
Dr. Georges	Animal Health Senior Expert, United Nations Food and Agriculture					
Khouri	Organization					
Dr. Hani Laham	AMR "Antibiotic Use Axis D" focal point Head of Epidemiological Studies and Emerging Diseases Department, Communicable Diseases Directorate, Ministry of Health					
Dr. Hotouf Tawashi	School Health Directorate, Ministry of Education					
Dr. Hazar Farouan	Director of Communicable Diseases Directorate, Ministry of Health					
Dr. Hussein Suleiman	Director of Animal Health Directorate, Ministry of Agriculture					
Dr. Issam Anjek	Infectious Diseases Division, Pediatric Hospital Ministry of Higher Education					
Dr. Mahmoud Al Hasan	Order of Pharmacists Representative					
Dr. Majd Naasan	Director of the Center for Strategic Health Studies, Ministry of Health					
Dr. Majed Bitar	Infection Control in Primary Healthcare Centers, Primary Care Directorate, Ministry of Health					
Dr. Mazen Dieb	Head of Animal Laboratory, Animal Health Directorate, Ministry of Agriculture					
MR Mostafa Ismail	Head of the Food Safety Department, Animal Health Directorate, Ministry of Agriculture					
Mrs. Rafida Shamat	Head of Environmental Health Department, Ministry of Environment					

Dr. Rasmieh	National Professional Officer, World Health Organization, AMR focal
Allahham	point
Dr. Razan Salota	Director of Pharmaceutical Affairs, Ministry of Health
Dr. Shebl	Head of Public Health Laboratories, Ministry of Health
Khouri	Head of Public Health Laboratories, Willistry of Health
Dr. Wahid Rajab	Head of the Infectious Diseases Department, Al-Moasat Hospital
Beak	Ministry of Higher Education

The National Action Plan is backed up the National Multi-sectoral Coordination Group:

- The Deputy of Minister of Health (Dr. Ahmad Khelfawy)
- The Director of Communicable Diseases Directorate, Ministry of Health (Dr. Hazar Farouan)
- The Head of Epidemiological Studies and Emerging Diseases Department, Communicable Diseases Directorate, Ministry of Health (Dr. Hani Laham)
- The Director of Hospital Directorate, Ministry of Health (Dr. Ahmad Domieria)
- Head of Public Health Laboratories, Ministry of Health (Dr. Shebl Khouri)
- Directorate of Pharmaceutical Affairs, Ministry of Health MOH (Dr. Razan Salota)
- Head of Infection Control Department, Hospital Directorate, Ministry of Health (Dr. Bashar Haj Ali)
- Ministry of Higher Education (Dr. Wahid Rajab Beak)
- Director of Animal Health Directorate, Ministry of Agriculture (Dr. Hussein Suleiman)
- Head of Environmental Health Department, Ministry of Environment (Mrs. Rafida Shamat)

### Acknowledgement:

The Ministry of Health extends its thanks and appreciation to all national partners from all relevant ministries, syndicates and the world health organization who participated in the preparation and development of antimicrobial resistance action plan. And all thanks and appreciation to the team of the Directorate of Communicable Diseases for efforts and diligent follow-up in order to launch the first national action plan to control the antimicrobial resistance.

# **Table of Content**

Abbreviations and acronyms	<b>p.5</b>
Executive summary	<b>p.6</b>
Introduction	<b>p.8</b>
Situation analyses and Assessment	<b>p.9</b>
Country Response	p.10
Axis A (Awareness)	
Strategic plan	p.15
Operational and budget plan	p.23
Monitoring and Evaluation plan	p.38
Axis B (Surveillance)	
Strategic plan	p.53
Operational and budget plan	p.61
Monitoring and Evaluation plan	<b>p.78</b>
Axis C (Infection prevention and Control)	
Strategic plan	p.94
Operational and budget plan	<b>p.10</b> 0
Monitoring and Evaluation plan	p.112
Axis D (Antibiotic Use)	
Strategic plan	p.125
Operational and budget plan	p.131
Monitoring and Evaluation plan	p.148
References	p.164

### Abbreviations and acronyms

**ABX**: Antibiotics

AMR: Antimicrobial resistance

CME: Continuous Medical Education

EMRO: Eastern Mediterranean Region Office

FAO: Food and Agriculture Organization

GAP: Global Action Plan

GLASS: Global Antimicrobial Resistance Surveillance System

**ID:** Infectious Diseases

**IPC:** Infection Prevention and Control

IT: Information Technology

**KPI**: Key Performance Indicator

LTCF: Long-Term Care Facilities

MOA: Ministry of Agriculture

MOH: Ministry of Health

MOE: Ministry of Education

MOHE: Ministry of Higher Education

NA: Not Available

NAP: National Action Plan

NGO: Non-governmental Organization

NMCG: National Multi-sectoral Coordination Group

OIE: World Organization for Animal Health

PHC: Primary Health Care

PHCC: Primary Health Care Center

QC: Quality Control

TOR: Terms of Reference

TV: Television

**UN: United Nations** 

UNRWA: United Nations Relief and Works Agency

**USD:** United States Dollars

WHO: World Health Organization

### **Executive Summary**

Syria is in the healing phase after a countrywide conflict that lasted so far 9 years. In 2019, there are still areas in the country where the hospitals and health systems are unreachable because of persistent conflict. The current AMR plan is made to cover all the areas that are reachable by the current official government. During the 9 years of conflict, there has been very little data from Syria about AMR. Despite being limited, the available data and information show that Syria is not spared from the global phenomenon of antimicrobial resistance (AMR).

A National Action Plan (NAP) has been put by the stakeholders of the country in the field, facilitated by the World Health Organization (WHO) under the umbrella of the Ministry of Health (MOH). The plan is tricyclic consistent with a "One Health" approach involving human and non-human sectors. The plan is in concordance with the WHO Global Action Plan (GAP) and follows the WHO template of having a strategic plan, an operational plan and a monitoring plan in each of the 4 axes (awareness, surveillance, infection prevention and control, and antibiotic use). The operational plan dissects each activity or sub-activity specifying the responsible entity or person, the time frame, the cost and the source of funding, with a corresponding quality key performance indicator (KPI) for monitoring if applicable.

The NAP in Syria is based first and foremost on elevating the problem of AMR to the level of national priorities, especially in this period where rebuilding of the organizational structure of the country is being carried on. Then, a basic preparation for the actual work is necessary, by starting from legislations, or reinforcement of available related legislations that were neglected or forgotten during the years of conflict.

In this NAP on AMR, the main objectives are:

- B. To improve AMR awareness among the authorities, the public, and the concerned professionals.
- C. To initiate an AMR surveillance system that ultimately can report to the Global Antimicrobial Resistance Surveillance System (GLASS) and generate its own local surveillance report. This is to be done through:
  - Reintroducing the culture of antibiograms in clinical specimens in human, veterinary and food specimens.
  - Including the cost of antibiogram into the budget of the health system.
  - Providing the needed material despite the current economic and trading Embargo on Syria.
  - Providing human capacity building by workshops and education opportunities to microbiologists and laboratory technicians.
  - Capacity building of the central laboratory to become a reference laboratory for AMR.
- D. To improve Infection Prevention and Control (IPC) in health care systems by introducing mandatory IPC programs in these premises and providing/requiring education in IPC of professionals.
- E. To improve antimicrobial use in humans, animals and agriculture by including activities that aim at:
  - Controlling the quality of the antimicrobial molecules that are available in the Syrian market.

- Providing treatment guidelines to professionals for the common infectious diseases (ID) and diffusing these guidelines in healthcare facilities, in addition to educational lectures about these guidelines.
- Introducing the idea of antimicrobial stewardship by restricting specific high priority antimicrobials to professionals who received education/training on its use.
- Controlling the use of antimicrobials in the community by restricting their dispensing in pharmacies to prescription-based dispensing, and education of primary care physicians about the treatment guidelines.
- Reinforcing OIE biosafety laws in the veterinary world.

The activities of different axes should be executed within the coming 5 years. Collaboration between the Syrian government and different non-governmental organizations (NGOs) like the Food and Agriculture Organization (FAO), the World Organisation for Animal Health (OIE), WHO and Aghakhan will be an asset towards the execution of the NAP on AMR.

### **Introduction**

Since 2012, the conflict in Syria has become the leading cause of death and injury. In the absence of accurate recent figures, it is estimated, as of the end of 2015, that 470,000 have been killed and 1.9 million injured (Syrian Center for Policy Research, 2018). With high rates of injury, the potential for infection is exacerbated by the crowded and often unsanitary conditions in health facilities, combined with the nature of injuries produced by heavy weaponry. Unfortunately, in such life threatening conditions, AMR emerges and spreads but remains neglected.

The destruction of health facilities, the death of healthcare workers, and the increasing fragmentation of Syria's health system have all contributed to the myriad of challenges in addressing AMR (Fouad et al., 2017). By April 2017, only 56 out of 111 public hospitals were still offering services (WHO, 2018), with a major decrease in the number of available Health care professionals.

Since2012, data on the availability and efficacy of antimicrobial therapy within Syria have become increasingly limited. Six studies from inside Syria since late 2011 have reported concerns over the increasing burden of resistant Gram-negative infections and methicillin-resistant Staphylococcus aureus (MRSA), four of these being focused on Aleppo (Alheib et al., 2015; Mahfoud et al., 2015; Al-Assil et al., 2013; Tabana et al., 2015). It is notable that few datasets from within Syria have reported on war-related injuries and their infectious complications; this is likely driven by several factors including the overwhelmed health systems.

Tackling AMR amongst Syrians inside Syria requires multifaceted action at the local, regional, and international levels through establishing a National Action Plan based on the "One Health" approach taking into consideration the local situation. Failing to address issues at the local level can have regional and global implications.

### Situation analyses and Assessment

Currently, Syria is a country in the process of recovery. Some parts of the country are still outside the control of the official government, and some others are still in war. Before 2012 AMR in Syria was not among the Health priorities, from 2011 until now, the conflict in the country stopped all health planning activities and the whole country was in an emergency situation. During the recovery period, the health officials consider that there are many priorities in Health other than AMR.

A major strength that can support any NAP is that the Syrian regime is strong and that ministerial decisions are respected and well taken by related stakeholders and employees. Another strong point is that the official structure of the health system before the conflict was very well organized, and there is a continuity in the structure of the system in the current situation. Also, the stakeholders believe in the power of the ministries and WHO. They have already participated in other national plans that were successful like the control of tuberculosis, polio, and meningitis, and a priori they believe that they can make a change with this NAP.

However, the weaknesses and threats are numerous. The ID specialists are few, not enough to cover the majority of the hospitals. Most of clinical microbiology labs lack microbiologists. In addition, hospitals consider that the equipment and material needed for antibiogram determination are expensive and therefore are not available. Automation machines are available but the material needed to run these machines are considered not affordable. Microbiological diagnosis in most of the hospitals is visual rather than biochemical, and as mentioned before, antibiograms are not being performed. Physicians start antibiotic therapy by intuition and if there is evidence of lack of response to therapy they escalate their treatment. On the other hand, most of the antibiotics available in the market are generic or copy drugs and there is a general lack of confidence among professionals that they are equivalent to brand antimicrobials.

There are opportunities for improving this situation. Because the officials consider the current period as a period of "healing", the stakeholders consider that the current period is a high time to introduce a plan into the overall national strategy. On the other hand, the presence of many NGOs in Syria at the time being, involved in health, agriculture and environment can be an opportunity to attract funds and to cooperate with these organizations in performing many activities of the AMR NAP, that can be part of their targets as well.

The persistence of the lack of security in some areas, and the presence of aggregates of people in areas outside the reach of the official authorities, will make the plan restricted to the areas of Syria that are under the official regime and the other areas will be left out. This non-uniformity in plan coverage in different areas of the country would be a threat to the outcome of the plan. On the other hand, the economic embargo that is imposed on Syria would make it difficult for the stakeholders to procure the necessary equipment, material and sometimes expertise that are needed in the field of AMR.

### **Country Response**

The Syrian Ministry of Health (MOH) has appointed the national multi-sectoral coordination group (NMCG) for AMR control in Syria. This group consists of representatives from the following ministries and departments:

- The Deputy of Minister of Health (Dr. Ahmad Khelfawy)
- The Director of Communicable Diseases Directorate, Ministry of Health (Dr. Hazar Farouan)
- The Head of Epidemiological Studies and Emerging Diseases Department, Communicable Diseases Directorate, Ministry of Health (Dr. Hani Laham)
- The Director of Hospital Directorate, Ministry of Health (Dr. Ahmad Domieria)
- Head of Public Health Laboratories, Ministry of Health (Dr. Shebl Khouri)
- Directorate of Pharmaceutical Affairs, Ministry of Health MOH (Dr. Razan Salota)
- Head of Infection Control Department, Hospital Directorate, Ministry of Health (Dr. Bashar Haj Ali)
- Ministry of Higher Education (Dr. Wahid Rajab Beak)
- Director of Animal Health Directorate, Ministry of Agriculture (Dr. Hussein Suleiman)
- Head of Environmental Health Department, Ministry of Environment (Mrs. Rafida Shamat)

In addition, the Syrian MOH has assigned four national AMR focal points:

- Axis A Awareness: Dr. Amer Teebi
- Axis B Surveillance: Dr. Fatima Mansour
- Axis C Infection Prevention and Control: Dr. Bashar Haj Ali
- Axis D Antibiotic Use: Dr. Hani Laham

In February 2019, a mission led by the WHO and Syrian MOH was undertaken whereby a 5-days workshop was held in Damascus. The workshop was facilitated by a WHO consultant and the Syrian members of the NMCG for AMR containment. The aim was to put a NAP in line with the WHO GAP for the fight against AMR.

# Governance

# **Strategic Plan**

Strategic objective	Activity	Sub-activity	Date (from operational plan)	Milestone
G.1 Establishment of the NMCG	G.1.1 Nomination and definition of functions of the NMCG	G.1.1.1 Nomination of the members of he NMCG	G.1.1 Achieved	G.1 1 month
		G.1.1.2 -Include the TOR of the NMCG in the official nomination -Include its function, authority and accountability to existing document	G.1.1.2 1 month	
	G.1.2 Appointment of the National Focal person of the NMCG	G.1.2.1 Official appointment of focal person	G.1.2.1 1 month	
		G.1.2.2 Specify the TOR of the focal person, and include them in the letter of appointment.	G.1.2.2 1 month	
G.2 Establish support for the NMCG with ministerial authorities	G.2.1 Involvement of higher authorities with AMR NAP, as support of NMCG	G.2.1.1 Briefing of the deputy of the minister about the NAP and put a road map for higher political support of the NMCG	G.2.1.1 2 months	G.2 2 months
G.3 Establish technical committees for the axes of awareness, IPC, surveillance, ABX use in "One Health" approach	G.3.1  Nominate committees and invite members for the meetings during the 1 <sup>st</sup> workshop for the NAP		G.3.1 10 <sup>th</sup> Feb 2019	G.3 10 <sup>th</sup> Feb 2019

## **Operational Plan**

Strategic objective	Activity	Sub- activity	Unit	Quantity	Date	Location	Responsibl e entity	Cost	Source of funding	Indicator
G.1 Establishm ent of the NMCG	G.1.1 Nomination and definition of functions of the NMCG	G.1.1.1 Nomination of the members of he NMCG	G.1.1 Nominatio n	G.1.1 1	G.1.1 Achieved					
		G.1.1.2 -Include the TOR of the NMCG in the official nomination -Include its function, authority and accountabil ity to existing document	G.1.1.2 Decree	G.1.1.2 1	G.1.1.2 1 month	G.1.1.2 MOH	G.1.1.2 -MOH -MOA -Ministry of environme nt	G.1.1.2 None	G.1.1.2	G.1.1 Decree is issued with specified TOR of the NMCG
	G.1.2 Appointme nt of the National Focal	G.1.2.1 Official appointmen t of focal person	G.1.2.1 Decree	G.1.2.1 1	G.1.2.1 1 month	G.1.2.1 MOH	G.1.2.1 -MOH -MOA -Ministry of	G.1.2.1 None	G.1.2.1	G.1.2 Focal Person appointed with

	person of the NMCG						environme nt			specified TOR
		G.1.2.2 Specify the TOR of the focal person, and include them in the letter of appointmen t.	G.1.2.2 Decree	G.1.2.2 1	G.1.2.2 1 month	G.1.2.2 MOH	G.1.2.2 -MOH -MOA -Ministry of environme nt	G.1.2.2 None	G.1.2.2	
G.2 Establish support for the NMCG with ministerial authorities	G.2.1 Involvemen t of higher authorities with AMR NAP, as support of NMCG	G.2.1.1 Briefing of the deputy of the minister about the NAP and put a road map for higher political support of the NMCG	G.2.1.1 Meeting	G.2.1.1 1	G.2.1.1 2 months	G.2.1.1 MOH MOA	G.2.1.1 -WHO AMR focal person (Dr. Rasmieh Allahham) -Focal person of NMCG (Dr.?) +/WHO Consultant/ Facilitator (Dr. Rima Moghnieh)	G.2.1.1 None	G.2.1.1	G.2.1.1 None
G.3 Establish technical working	G.3.1 Nominate technical working		G.3.1 Nominatio	G.3.1 4 technical working groups	G.3.1 10 <sup>th</sup> Feb 2019	G.3.1 Workshop meeting venue	G.3.1 -NMCG -WHO Consultant/	G.3.1 None	G.3.1	G.3.1 None

groups for	groups and			(Dam	Facilitator		
the axes of	invite			Rose)	(Dr. Rima		
awareness,	members				Moghnieh)		
IPC,	for the						
surveillanc	meetings						
e, ABX use	during the						
in "One	$1^{st}$						
Health"	workshop						
approach	for the						
	NAP						

# Axis A (Awareness)

# Strategic plan

Strategic objective	Activity	Sub-activity	Date	Milestone
A.1 Organization of the tasks in this axis	A.1.1 Establishing the technical working group	A.1.1.1 Nomination	A.1.1.1 1 month	A.1 1 month
		A.1.1.2 Putting TOR	A.1.1.2 1 month	
		A.1.1.3 Assigning focal point (Dr. Amer Teebi)	A.1.1.3 1 month	
A.2 Include AMR awareness in the national school education system	A.2.1 Education in schools	A.2.1.1 Letter from MOH to MOE to send a mandate to the school curricula committee to include AMR awareness in school curricula (Dr. Tabbah)	A.2.1.1 1 month	A.2 9 months
	A.2.2 Preparation of education material for the different levels and specialization in higher education and to train the educators about AMR	A.2.2.1 Preparation of material AMR/IPC Material according to each specialization: Medical school, Pharmacy students, Nursing, Dentists Veterinarians	A.2.2.1 1 month	

	A.2.3 To sensitize And train educators in schools and higher education about teaching about AMR.	A.2.3.1 Training of trainers and educators through workshops for all school activities related to AMR	A.2.3.1 6 months	
		A.2.3.2 Training of employees in the sectors of education by trained profession in the TOT central training	A.2.3.2 9 months	
A.3 Fortify the awareness about AMR in the human medical education	A.3.1 Medical schools: Include AMR projects in health education projects that are required to be prepared by medical students in their 5 <sup>th</sup> /6 <sup>th</sup> year of medical school	A.3.1.1 Recommendation to medical schools program director	A.3.1.1 2 months	A.3 2 months
	A.3.2 To give a lecture to medical students when they start their clinical work at the 6 <sup>th</sup> year of Medical school, once they reach primary health care to be distributed to the different specialties for training	A.3.2.1 Include lecture /year/trainee about AMR	A.3.2.1 2 months	
	A.3.3 -To include AMR Awareness in the preparatory course for the medical students that are graduates from abroad and	A.3.3.1  Letter from NMCG and  MOH to  رئيس الهيئة الصحية للتخصصات	A.3.3.1 2 months	

	who need to sit for colloquium -To include AMR questions in the colloquium exam  الهيئة الصحية للتخصصات الطبية مسؤولة عن هذا في الدورة التدريبية وأسئلة امتحان الكولوكيوم			
	A.3.4 Include AMR questions in colloquium exams	A.3.4.1 Letter to دائرة الامتحاثات	A.3.4.1 1 month	
A.4 To fortify the education about AMR in veterinary schools	A.4.1 Veterinary schools: Include AMR projects in education projects that are required to be prepared by students in their 5 <sup>th</sup> /6 <sup>th</sup> year of veterinary school programs	A.4.1.1 Acquire acceptance from MOE	A.4.1.1 2 months	A.4 2 months
	A.4.2	A.4.2.1	A.4.2.1 2 months	

A S D : AND	To train veterinarians about AMR at the level of 6 <sup>th</sup> year when they start their practical training	Letter from MOA to مديرية الصحة الحيوانية في المحافظات Students in 5th/6th year in training/ lecture A.5.1.1		
A.5 Raise AMR awareness among veterinarians and farmers outside official veterinary school training	A.5.1 Workshops targeting veterinarians and farmers	To include AMR awareness in the yearly program of مديرية تأهيل وتدريب الأطباء البيطريين	A.5.1.1 1 year	A.5 1 year
A.6 AMR awareness in higher education specializations	A.6.1 To recommend to Ministry of Higher Education to include AMR education and hygiene in the basic education of medical doctors, pharmacists, dentists, nurses, midwives, veterinarians and students in the agriculture and environment fields (according to material prepared in A.2.2)	A.6.1.1 Letter from MOH to Ministry of higher education to include AMR in the curricula of health related specializations as listed	A.6.1.1 3 months	A.6 1 year
	A.6.2 Include AMR awareness material in health and hygiene education program outside the official curricula	A.6.2.1 Letter to MOE to include information on AMR in health education outside curricula	A.6.2.1 1 year	
A.7 AMR education in continuous education programs	A.7.1 Ask Syndicates/Orders of Physicians, Pharmacist, Nurses, Veterinarians to	A.7.1.1 Letter from NMCG/MOH/MOA to these orders/syndicates to include	A.7.1.1 1 month	A.7 1 year 3 months

include information on AMR in their continuous education programs	information on AMR in their continuous education programs		
	A.7.1.2 To ask these s orders/syndicates to give lectures once/year in each specialty about AMR	A.7.1.2 1 month	
	A.7.1.3  Send a letter to the organizing committee of the yearly congress of the Syrian Order of Physicians to include lectures on AMR اللجنة العلمية المؤتمر السنوي للأطباء في سوريا	A.7.1.3 3 months	
	A.7.1.4  Send a letter to the organizing committee of the yearly congress of the Syrian Order of Veterinarians to include lectures on AMR اللجنة العلمية المؤتمر السنوي للطب البيطري في سوريا	A.7.1.4 3 months	

		A.7.1.5 Trained personnel give AMR lectures in all sectors covered	A.7.1.5 1 year 3 months	
A.8 Improve AMR awareness among professionals in human health sectors	A.8.1 Raise AMR awareness among primary care physicians أطباء المستوصفات	A.8.1.1 Send a letter to مديرية الأمراض السارية في المستوصفات المستوصفات Department of communicable diseases	A.8.1.1 1 month	A.8 5 years
		A.8.1.2 Letter from مديرية الأمراض السارية في المستوصفات to WHO to organize yearly activities on AMR for physicians and relevant personnel in the primary care field	A.8.1.2 a-1 month b-5 years	
	A.8.2 Improve AMR awareness for employees of dispensaries, NGOs like, الهلال الاحمر, Red Cross, MSF, UNRWA, Religious foundations/organizations	A.8.2.1 Workshop to the employees of these NGOs about AMR	A.8.2.1 2 months	
A.9 To improve AMR awareness among farmers	A.9.1 To include AMR information among the lectures given to farmers by الارشاد الزراعي	A.9.1.1 Letter from MOA to الارشاد الزراعي to include AMR information in their weekly lectures	A.9.1.1 1 month	A.9 1 month
A.10 To raise public awareness about AMR	A.10.1 To include	A.10.1.1 To prepare the message	A.10.1.1 3 months	A.10 6 months

a	AMR Awareness in antibiotic leaflets			
	النشرة الطبية للمضادات الحيوية	A.10.1.2  To send a letter to مديرية الشؤون الصيدلانية to include this message in the ABX leaflets	A.10.1.2 1 month	
I t	A.10.2 Preparation of material for billboards, radio, TV, social media	A.10.2.1 Launch a competition for the public to prepare material for broadcasting and logo	A.10.2.1 3 months	
		A.10.2.2  To advertise for the competition on TV news, social media, official Newspaper	A.10.2.2 3 months	
		A.10.2.3 Put a yearly schedule for broadcasting the chosen advertisement material throughout the year and concentrate on it during the Global Week for AMR and book the spots for it	A.10.2.3 6 months	
I	A.10.3 Improve awareness of the media employees about AMR	A.10.3.1 Workshop to media employees	A.10.3.1 6 months	

A.10.4 Have a celebrity talk about AMR	A.10.4.1 Choose and approach a celebrity to talk frequently about AMR	A.10.4.1 6 months	
A.10.5 To create a page for AMR included in the MOH and MOA websites where all information, studies, news are broadcasted	A.10.5.1  Letter from the technical working group to المكتب التابع لوزارة الصحة	A.10.5.1 1 month	

# **Operational plan and budget**

Strategic objective	Activity	Sub- activity	Unit	Quantity	Date	Location	Responsibl e entity	Cost	Source of funding	Indicator
A.1 Organizatio n of the tasks in this axis	A.1.1 Establishin g the technical working group	A.1.1.1 Nomination	A.1.1.1 Nominatio n letter with the list of members	A.1.1.1 1	A.1.1.1 1 month	A.1.1.1 MOH MOA	A.1.1.1 NMCG	A.1.1.1 None	A.1.1.1	A.1 Working group and focal person nominated
		A.1.1.2 Putting TOR	A.1.1.2 List of TOR inside nomination letter	A.1.1.2 1	A.1.1.2 1 month	A.1.1.2 MOH MOA	A.1.1.2 NMCG	A.1.1.2 None	A.1.1.2	
		A.1.1.3 Assigning focal point (Dr. Amer Teebi)	A.1.1.3 Nominatio n letter	A.1.1.3 1	A.1.1.3 1 month	A.1.1.3 MOH MOA	A.1.1.3 NMCG	A.1.1.3 None	A.1.1.3	
A.2 Include AMR awareness in the national school education system	A.2.1 Education in schools	A.2.1.1 Letter from MOH to MOE to send a mandate to the school curricula committee to include AMR awareness	A.2.1.1 Letter	A.2.1.1 1	A.2.1.1 1 month	A.2.1.1 MOE	A.2.1.1 Dr. Hotouf Tawashi (School Health Directorate, MOE)	A.2.1.1 None	A.2.1.1	A.2.1, A.2.2 Percentage of school programs/c urricula that include AMR education

	in school curricula (Dr Tabbah)								
A.2.2 Preparation of education material for the different levels and specializati on in higher education and to train the educators about AMR	A.2.2.1 Preparation of material AMR/IPC Material according to each specializati on: Medical school, Pharmacy students, Nursing, Dentists Veterinaria ns	A.2.2.1 List	A.2.2.1 1	A.2.2.1 1 month	A.2.2.1 MOH MOA	A.2.2.1 Technical working group	A.2.2.1 None	A.2.2.1	
A.2.3 To sensitize And train educators in schools and higher education about teaching	A.2.3.1 Training of trainers and educators through workshops for all school activities	A.2.3.1 Training of trainers (TOT) workshops	A.2.3.1 2	A.2.3.1 6 months	A.2.3.1 Damascus	A.2.3.1 Dr. Hotouf Tawashi (School Health Directorate, MOE)	A.2.3.1 5000 USD/works hop	A.2.3.1 AMR Fund	A.2.3 Percentage of education sector employees that have attended training

	about AMR.	related to AMR								sessions about AMR
		A.2.3.2 Training of employees in the sectors of education by trained profession in the TOT central training	A.2.3.2 Workshops in the different Governorat es	A.2.3.2 8	A.2.3.2 9 months	A.2.3.2 Different Governorat es	A.2.3.2 Trained personnel (TOT)	A.2.3.2 500 USD/ workshop Total= 4,000 USD	A.2.3.2 AMR Fund	
A.3 Fortify the awareness about AMR in the human medical education	A.3.1 Medical schools: Include AMR projects in health education projects that are required to be prepared by medical students in their 5th/6th year of medical school	A.3.1.1 Recommen dation to medical schools program director	A.3.1.1 Letter	A.3.1.1	A.3.1.1 2 months	A.3.1.1 MOE	A.3.1.1 Dr. Hotouf Tawashi (School Health Directorate, MOE)	A.3.1.1 None	A.3.1.1	A.3.1.1 Percentage of 5 <sup>th</sup> /6 <sup>th</sup> year medical school projects that are related to AMR
	A.3.2	A.3.2.1	A.3.2.1	A.3.2.1	A.3.2.1	A.3.2.1	A.3.2.1	A.3.2.1	A.3.2.1	A.3.2.1

To give a lecture to medical students when they start their clinical work at the 6 <sup>th</sup> year of Medical school, once they reach primary	Include lecture /year/traine e about AMR	Letter from MOH to primary health care directorate to include this lecture in primary health care where all 6th year medical student have to go	1	2 months	МОН	Technical working group NMCG	None		None
health care to be distributed to the different		through							
specialties for training									
A.3.3 -To include AMR Awareness in the preparatory course for the medical students that are graduates	A.3.3.1  Letter from NMCG and MOH to رئيس الهيئة الصحية للتخصصات الطبية	A.3.3.1 Letter	A.3.3.1 1	A.3.3.1 2 months	A.3.3.1 MOH	A.3.3.1 NMCG	A.3.3.1 None	A.3.3.1	A.3.3.1 None

from abroad and who need to sit for colloquium -To include AMR questions in the colloquium exam  الهيئة الصحية التخصصات الطبية مسؤولة التخريبية التدريبية الكولوكيوم									
A.3.4 Include AMR questions in colloquium exams	A.3.4.1 Letter to دائرة الامتحانات	A.3.4.1 Letter	A.3.4.1 1	A.3.4.1 1 month	A.3.4.1 MOH	A.3.4.1 Technical working group	A.3.4.1 None	A.3.4.1	A.3.4.1 Yes/No questions about AMR in colloquium exam

A.4 To fortify the education about AMR in veterinary schools	A.4.1 Veterinary schools: Include AMR projects in education projects that are required to be prepared by students in their 5th/6th year of veterinary school programs	A.4.1.1 Acquire acceptance from MOE	A.4.1.1 Letter	A.4.1.1 1	A.4.1.1 2 months	A.4.1.1 MOE	A.4.1.1 Dr. Hotouf Tawashi (School Health Directorate, MOE)	A.4.1.1 None	A.4.1.1	A.4.1.1 Percentage of 5 <sup>th</sup> /6 <sup>th</sup> year veterinary school projects that are related to AMR
	A.4.2 To train veterinarian s about AMR at the level of 6 <sup>th</sup> year when they start their practical training	A.4.2.1 Letter from MOA to مديرية الصحة الحيوانية في المحافظات Students in 5 <sup>th</sup> /6 <sup>th</sup> year in training/ lecture	A.4.2.1 Letter	A.4.2.1 1	A.4.2.1 2 months	A.4.2.1 MOA	A.4.2.1 Technical working group	A.4.2.1 None	A.4.2.1	A.4.2.1 None
A.5 Raise AMR awareness	A.5.1 Workshops targeting	A.5.1.1 To include AMR	A.5.1.1 Program	A.5.1.1 1/year	A.5.1.1 1 year	A.5.1.1 MOA	A.5.1.1 MOA	A.5.1.1 2000 USD/year	A.5.1.1 AMR Fund	A.5.1.1 Percentage of farmers

among veterinarian s and farmers outside official veterinary school training	veterinarian s and farmers	awareness in the yearly program of مديرية تأهيل وتدريب الأطباء								and veterinaria ns who attend these workshops
A.6 AMR awareness in higher education specializati ons	A.6.1 To recommend to Ministry of Higher Education to include AMR education and hygiene in the basic education of medical doctors, pharmacists , dentists, nurses, midwives, veterinarian s and students in the	A.6.1.1 Letter from MOH to Ministry of higher education to include AMR in the curricula of health related specializati ons as listed	A.6.1.1 Letter	A.6.1.1 1	A.6.1.1 3 months	A.6.1.1 MOH	A.6.1.1 NMCG MOH	A.6.1.1 None	A.6.1.1	A.6 Percentage of heath related curricula that include modules about AMR

	agriculture and environmen t fields (according to material prepared in A.2.2)									
	A.6.2 Include AMR awareness material in health and hygiene education program outside the official curricula	A.6.2.1 Letter to MOE to include information on AMR in health education outside curricula	A.6.2.1 Letter from technical working group represented by Dr. Hotouf Tawashi (School Health Directorate, MOE) to the Minster of Education	A.6.2.1 1	A.6.2.1 1 year	A.6.2.1 MOE	A.6.2.1 Dr. Hotouf Tawashi (School Health Directorate, MOE)	A.6.2.1 None	A.6.2.1	
A.7 AMR education in continuous education programs	A.7.1 Ask Syndicates/ Orders of Physicians, Pharmacist, Nurses,	A.7.1.1 Letter from NMCG/M OH/MOA to these orders/synd icates to	A.7.1.1 Letter	A.7.1.1 1	A.7.1.1 1 month	A.7.1.1 MOH MOA	A.7.1.1 NMCG MOH MOA	A.7.1.1 None	A.7.1.1	A.7 Percentage of activities/se ssions/ lectures that include

Veterinaria ns to include information on AMR in their continuous education programs	information on AMR in their								messages about AMR
	A.7.1.2 To ask these s orders/synd icates to give lectures once/year in each specialty about AMR	A.7.1.2 Letter	A.7.1.2 1	A.7.1.2 1 month	A.7.1.2 MOH MOA	A.7.1.2 Technical working group NMCG MOH MOA	A.7.1.2 None	A.7.1.2	
	A.7.1.3 Send a letter to the organizing committee of the yearly congress of the Syrian Order of Physicians	A.7.1.3 Letter	A.7.1.3 1	A.7.1.3 3 months	A.7.1.3 MOH	A.7.1.3 Technical working group	A.7.1.3 None	A.7.1.3	

to include lectures of AMR جنة العلمية يتمر نوي لباء في ريا	أن الم الم الس للأ							
A.7.1.4 Send a letter to the organizing committee of the yearly congress the Syrian Order of Veterinary in site of include lectures of AMR الموتمر ال	of A.7.1.4 Letter	A.7.1.4 1	A.7.1.4 3 months	A.7.1.4 MOH MOA	A.7.1.4 Technical working group NMCG MOA	A.7.1.4 None	A.7.1.4	
A.7.1.5 Trained personne give AM		A.7.1.5 4 workshops /year	A.7.1.5 1 year 3 months	A.7.1.5 Different governorate s	A.7.1.5 MOA	A.7.1.5 500 USD/ Workshop	A.7.1.5 AMR Fund	

A.8 Improve AMR awareness among professiona ls in human health sectors	A.8.1 Raise AMR awareness among primary care physicians المستوصفات	lectures in all sectors covered  A.8.1.1 Send a letter to مديرية الأمراض المدرية في الأمراض المستوصفات Oppartment of communica ble diseases	A.8.1.1 Letter	A.8.1.1 1	A.8.1.1 1 month	A.8.1.1 MOH	A.8.1.1 MOH	A.8.1.1 None	A.8.1.1	A.8.1 Percentage of primary care physicians who attend sessions/act ivities/ workshops related to AMR
		A.8.1.2  Letter from مديرية الأمراض الأمراض السارية في المستوصفات المستوصفات to WHO to organize yearly activities on AMR for physicians and relevant personnel in the	A.8.1.2 a-Letter b- Workshops	A.8.1.2 a-1 b-9/year	A.8.1.2 a-1 month b-5 years	A.8.1.2 MOH	A.8.1.2 MOH	A.8.1.2 9 workshops/ year 2,500 USD/ workshop	A.8.1.2 AMR Fund	

		primary care field								
	A.8.2 Improve AMR awareness for employees of dispensarie s, NGOs like, וلخصر الهلال, Red Cross, MSF, UNRWA, Religious foundations /organizatio ns	A.8.2.1 Workshop to the employees of these NGOs about AMR	A.8.2.1 Workshop to all available in Damascus	A.8.2.1 4 workshops/ year  1st year to increase with time depending on the number of areas that are reachable according to safety conditions	A.8.2.1 2 months	A.8.2.1 Damascus and expanding to safe areas outside Damascus	A.8.2.1 Technical working group	A.8.2.1 2,500 USD /workshop First 2 years 4 workshops/ year	A.8.2.1 AMR Fund	A.8.2 Percentage of employees of these organizations that attend these workshops
A.9 To improve AMR awareness among farmers	A.9.1 To include AMR information among the lectures given to farmers by الإرشاد	A.9.1.1 Letter from MOA to الارشاد الزراعي to include AMR information in their weekly lectures	A.9.1.1 Letter	A.9.1.1 1	A.9.1.1 1 month	A.9.1.1 MOA	A.9.1.1 Technical working group	A.9.1.1 None	A.9.1.1	A.9.1.1 Letter sent and % of lectures given including AMR messages

A.10 To raise public awareness about AMR	AMR Awareness in antibiotic leaflets النشرة الطبية المضادات الحيوية	A.10.1.1 To prepare the message	A.10.1.1 Document	A.10.1.1 1	A.10.1.1 3 months	A.10.1.1 MOH	A.10.1.1 Technical working group	A.10.1.1 None	A.10.1.1 None	A.10.1 Percentage of ABX that include AMR awareness in their leaflet
		A.10.1.2 To send a letter to مديرية الشؤون الصيدلانية to include this message in the ABX leaflets	A.10.1.2 Letter	A.10.1.2 1	A.10.1.2 1 month	A.10.1.2 MOH	A.10.1.2 Technical working group	A.10.1.2 None	A.10.1.2 None	
	A.10.2 Preparation of material for billboards, radio, TV, social media	A.10.2.1 Launch a competition for the public to prepare material for broadcastin g and logo A.10.2.2	A.10.2.1 Public competition	A.10.2.1 1	A.10.2.1 3 months  A.10.2.2	A.10.2.1 All over the safe area	A.10.2.1 MOH MOA وزارة الاعلام A.10.2.2	A.10.2.1 1,000 USD	A.10.2.1 AMR Fund	A.10.2.1 None

	To advertise for the competition on TV news, social media, official Newspaper	Advertisem ent campaign	1	3 months	All over the safe area	MOH MOA وزارة الاعلام	Included in A.10.2.1	AMR Fund	None
	A.10.2.3 Put a yearly schedule for broadcastin g the chosen advertisem ent material throughout the year and concentrate on it during the Global Week for AMR and book the spots for it	A.10.2.3 Schedule and booking	A.10.2.3 1	A.10.2.3 6 months	A.10.2.3 المكتب الإعلامي التابع لوزارة الصحة		A.10.2.3 To be assigned later	A.10.2.3 AMR Fund	A.10.2.3 Schedule is put and spots are booked
A.10.3 Improve awareness	A.10.3.1	A.10.3.1 Workshop	A.10.3.1 2/year	A.10.3.1 6 months	A.10.3.1 MOH MOA	A.10.3.1	A.10.3.1 2,500 USD/ workshop	A.10.3.1 AMR Fund	A.10.3.1 Percentage of

of the media employees about AM					WHO	Technical working group المكتب المكتب			employees who attend the sessions related to AMR
A.10.4 Have a celebrity talk about AMR	A.10.4.1 Choose and approach a celebrity to talk frequently about AMR	A.10.4.1 Person	A.10.4.1 1	A.10.4.1 6 months	A.10.4.1 Damascus	A.10.4.1 Technical working group	A.10.4.1 None	A.10.4.1	awareness  A.10.4.1  Number of sessions/ appearance s of this person when he/she talks about AMR
A.10.5 To create a page for AMR included in the MOH and MOA websites where all information, studies, news are broadcaste	A.10.5.1  Letter from the technical working group to المكتب المكتب التابع الوزارة الصحة لوزارة الصحة الوزارة الصحة المينانية	A.10.5.1 Letter	A.10.5.1 1	A.10.5.1 1 month	A.10.5.1 MOH	A.10.5.1 Technical working group NMCG	A.10.5.1 None	A.10.5.1	A.10.5.1 Letter sent and webpage created

## Monitoring and evaluation plan

Strategic objective	Activity	Sub-activity	Indicator	Purpose	Calculation	Frequency	Data source	Method	Baseline
A.1 Organization of the tasks in this axis	A.1.1 Establishing the technical working group	A.1.1.1 Nomination	A.1 Working group and focal person nominated	A.1 To organize and follow up the activities of this axis	A.1 Yes/No	A.1 Once/3 months until appointment	A.1 MOH	A.1 Checking	A.1 Not officially nominated
		A.1.1.2 Putting TOR							
		A.1.1.3 Assigning focal point (Dr. Amer Teebi)							
A.2 Include AMR awareness in the national school education system	A.2.1 Education in schools	A.2.1.1 Letter from MOH to MOE to send a mandate to the school curricula committee to include AMR awareness in school curricula (Dr Tabbah)	A.2.1, A.2.2 Percentage of school programs/cur ricula that include AMR education	A.2.1, A.2.2 To raise AMR awareness in an early stage at school	A.2.1, A.2.2 Number of school curricula that include AMR education/To tal number of school curricula	A.2.1, A.2.2 Once /2 years	A.2.1, A.2.2 MOE	A.2.1, A.2.2 Survey	A.2.1, A.2.2 Unknown

of edimater the di levels specin in he educa and to the education about	aration lucation rial for ifferent s and falizatio higher ation to train ducators t AMR	fedical chool, harmacy udents, fursing, entists feterinarian							
school highe educa about teach	tize Tr train tra ators in ed ols and thi er wo ation for t aci ning rel t AMR. AM	raining of ainers and ducators arough corkshops or all school ctivities elated to MR	A.2.3 Percentage of education sector employees that have attended training sessions about AMR	A.2.3 To increase awareness of educators about AMR	A.2.3 Number of schools that have given awareness sessions to their employees about AMR	A.2.3 Once/ year	A.2.3 Schools MOE	A.2.3 Survey	A.2.3 NA
	Tr en the	raining of mployees in the sectors of ducation by							

		trained profession in the TOT central training							
A.3 Fortify the awareness about AMR in the human medical education	A.3.1 Medical schools: Include AMR projects in health education projects that are required to be prepared by medical students in their 5th/6th year of medical school	A.3.1.1 Recommend ation to medical schools program director	A.3.1.1 Percentage of 5th/6th year medical school projects that are related to AMR	A.3.1.1 To raise AMR awareness among medical students at the stage of clinical work training	A.3.1.1 Number of 5 <sup>th</sup> /6 <sup>th</sup> year medical school projects that are related to AMR/Total number of projects	A.3.1.1 Once/ year	A.3.1.1 Medical schools	A.3.1.1 Survey	A.3.1.1 NA
	A.3.2 To give a lecture to medical students when they start their clinical work at the 6 <sup>th</sup>	A.3.2.1 Include lecture /year/trainee about AMR	A.3.2.1 None						

C					
year of					
Medical					
school, once					
they reach					
primary					
health care					
to be					
distributed to					
the different					
specialties					
for training					
A.3.3					
-To include					
AMR					
Awareness					
in the					
preparatory					
course for	A.3.3.1				
the medical	Letter from				
students that	NMCG and				
are graduates	MOH to				
from abroad	رئيس الهيئة	A.3.3.1			
and who	ريس بهيد الصحية	None			
need to sit	للتخصصات				
for	الطبية				
colloquium					
-To include					
AMR					
questions in the					
colloquium					
exam					

	الهيئة الصحية التخصصات الطبية مسؤولة عن هذا في الدورة التدريبية وأسئلة امتحان الكولوكيوم								
	A.3.4 Include AMR questions in colloquium exams	A.3.4.1 Letter to دائرة الامتحاثات	A.3.4.1 Yes/No questions about AMR in colloquium exam	A.3.4.1 Raise AMR awareness among new coming physicians, while preparing for the colloquium exam	A.3.4.1 Yes/No	A.3.4.1 Once/year	A.3.4.1 Colloquium exam committee	A.3.4.1 Survey	A.3.4.1 NA
A.4 To fortify the education about AMR in veterinary schools	A.4.1 Veterinary schools: Include AMR projects in education projects that are required to be prepared by students in their 5 <sup>th</sup> /6 <sup>th</sup>	A.4.1.1 Acquire acceptance from MOE	A.4.1.1 Percentage of 5 <sup>th</sup> /6 <sup>th</sup> year veterinary school projects that are related to AMR	A.4.1.1 To raise AMR awareness among veterinary school students at the stage of clinical work training	A.4.1.1  Number of 5 <sup>th</sup> /6 <sup>th</sup> year veterinary school projects that are related to AMR/Total number of projects	A.4.1.1 Once/ year	A.4.1.1 Veterinary schools	A.4.1.1 Survey	A.4.1.1 NA

	year of veterinary school programs								
	A.4.2 To train veterinarians about AMR at the level of 6 <sup>th</sup> year when they start their practical training	A.4.2.1 Letter from MOA to مديرية الصحة الحيوانية في الحيانية في المحافظات Students in 5th/6th year in training/ lecture	A.4.2.1 None						
A.5 Raise AMR awareness among veterinarians and farmers outside official veterinary school training	A.5.1 Workshops targeting veterinarians and farmers	A.5.1.1 To include AMR awareness in the yearly program of مديرية تأهيا وتدريب الأطباء	A.5.1.1 Percentage of farmers and veterinarians who attend these workshops	A.5.1.1 To increase AMR awareness among this group	A.5.1.1 Number of farmers and veterinarians who attend workshops/ Total number of farmers and veterinarians	A.5.1.1 Once/year	A.5.1.1 مديرية تأهيل وتدريب الأطباء البيطريين	A.5.1.1 Survey	A.5.1.1 NA

A.6 AMR awareness in higher education specializatio ns	A.6.1 To recommend to Ministry of Higher Education to include AMR education and hygiene in the basic education of medical doctors, pharmacists, dentists, nurses, midwives, veterinarians and students in the agriculture and environment fields (according to material prepared in A.2.2)  A.6.2	A.6.1.1 Letter from MOH to Ministry of higher education to include AMR in the curricula of health related specializations as listed  A.6.2.1	A.6 Percentage of heath related curricula that include modules about AMR	A.6 To increase awareness since university and college about AMR	A.6 Number of heath related curricula that include modules about AMR /Total number of health related curricula	A.6 Once/Year	A.6 Ministry of higher education	A.6 Survey	A.6 NA
	Include	Letter to							

	AMR awareness material in health and hygiene education program outside the official curricula	MOE to include information on AMR in health education outside curricula							
A.7 AMR education in continuous education programs	A.7.1 Ask Syndicates/O rders of Physicians, Pharmacist, Nurses, Veterinarian s to include information on AMR in their continuous education programs	A.7.1.1 Letter from NMCG/MO H/MOA to these orders/syndicates to include information on AMR in their continuous education programs	A.7 Percentage of activities/ses sions/ lectures that include messages about AMR	A.7 To raise AMR awareness among healthcare workers/prof essionals outside the education curricula	A.7 Number of activities lectures that include messages about AMR/Total number of activities	A.7 Once/year for each specialty	A.7 Orders/syndicates	A.7 Survey	A.7 NA

		ı		
A.7.1.2 To ask these s orders/syndi cates to give lectures once/year in each specialty about AMR				
A.7.1.3  Send a letter to the organizing committee of the yearly congress of the Syrian Order of Physicians to include lectures on AMR  اللجنة العلمية المؤتمر السنوي المؤتمر السنوي للأطباء في سوريا				
A.7.1.4 Send a letter to the				

		organizing committee of the yearly congress of the Syrian Order of Veterinarian s to include lectures on AMR قاللات اللغامية المؤتمر السنوي الطب البيطري للطب البيطري للطب البيطري الموتعر A.7.1.5 Trained personnel give AMR lectures in all sectors covered							
A.8 Improve AMR awareness among professionals in human health sectors	A.8.1 Raise AMR awareness among primary care physicians اطباء	A.8.1.1 Send a letter to مديرية الأمراض السارية في المستوصفات Department of communicab le diseases	A.8.1 Percentage of primary care physicians who attend sessions/acti vities/ workshops related to AMR	A.8.1 To increase awareness of primary care physicians, since they are the primary ABX prescribers	A.8.1 Number of primary care physicians who attend workshops related to AMR/Total number of primary care physicians	A.8.1 Once/year	A.8.1 MOH مديرية الأمراض السارية في المستوصفات	A.8.1 Survey	A.8.1 NA

			in the community					
	A.8.1.2  Letter from المراض المعنوصة الأمراض المستوصقات المستوصة المستوصقات المستوصة المستو							
A.8.2 Improve AMR awareness for employees of dispensaries, NGOs like, الاحبر الهلال, Red Cross, MSF, UNRWA, Religious foundations/	A.8.2.1 Workshop to the employees of these NGOs about AMR	A.8.2 Percentage of employees of these organization s that attend these workshops	A.8.2 To increase awareness of NGOs about AMR	A.8.2 Number employees of these organization s that attend these workshops/ Total number of employees	A.8.2 Once/year	A.8.2 NGO	A.8.2 Survey	A.8.2 NA

	organization s								
A.9 To improve AMR awareness among farmers	A.9.1 To include AMR information among the lectures given to farmers by الارشاد الزراعي	A.9.1.1 Letter from MOA to الارشاد الزراعي to include AMR information in their weekly lectures	A.9.1.1 Letter sent and % of lectures given including AMR messages	A.9.1.1 To focus farmers' knowledge about AMR in their field	A.9.1.1 Number of lectures that include AMR messages/tot al number of lectures given	A.9.1.1 Once/year	A.9.1.1 MOA الارشاد الزراعي	A.9.1.1 Checking and survey	A.9.1.1 NA
A.10 To raise public awareness about AMR	A.10.1 To include AMR Awareness in antibiotic leaflets  النشرة الطبية للمضادات	A.10.1.1 To prepare the message	A.10.1 Percentage of ABX that include AMR awareness in their leaflet	A.10.1 To involve pharmaceuti cal companies in raising public/profes sional awareness about AMR through reading the leaflets	A.10.1 Number of ABX products that include AMR awareness in their leaflet/ Total number of ABX products in the Syrian market	A.10.1 Once/year	A.10.1 MOH Pharmaceuti cal companies	A.10.1 Checking	A.10.1 NA
		A.10.1.2 To send a letter to مديرية الشؤون الصيدلانية							

	to include this message in the ABX leaflets							
A.10.2 Preparation of material for billboards, radio, TV, social med	A.10.2.1 Launch a competition for the public to prepare material for	A.10.2.1 None						
	A.10.2.2 To advertise for the competition on TV news, social media, official Newspaper	A.10.2.2 None						
	A.10.2.3 Put a yearly schedule for broadcasting the chosen advertisemen t material throughout the year and concentrate on it during	A.10.2.3 Schedule is put and spots are booked	A.10.2.3 To have a year long schedule of awareness sessions for the public on media	A.10.2.3 Yes/No	A.10.2.3 Once/year	A.10.2.3 MOH	A.10.2.3 Checking	A.10.2.3 NA

	the Global Week for AMR and book the spots for it							
A.10.3 Improve awareness of the media employees about AMR	A.10.3.1 Workshop to media employees	A.10.3.1 Percentage of employees who attend the sessions related to AMR awareness	A.10.3.1 To sensitize the media about AMR in order to motivate them to talk/publish about AMR and cover AMR events	A.10.3.1 Number of media employees who attend these workshops/ Total number of media employees	A.10.3.1 Once/year	A.10.3.1 MOH	A.10.3.1 Survey	A.10.3.1 NA
A.10.4 Have a celebrity talk about AMR	A.10.4.1 Choose and approach a celebrity to talk frequently about AMR	A.10.4.1 Number of sessions/ appearances of this person when he/she talks about AMR	A.10.4.1 To involve celebrities/p ublic figures to talk about AMR due to their influence on the public	A.10.4.1 Number of appearances of this person when he/she talks about AMR/Total number of appearances	A.10.4.1 Once/year	A.10.4.1 MOH	A.10.4.1 Checking	A.10.4.1 NA
A.10.5 To create a page for AMR included in the MOH	A.10.5.1 Letter from the technical working group to ورامانية	A.10.5.1 Letter sent and webpage created	A.10.5.1 To have an online site where activities about AMR	A.10.5.1 Yes/No	A.10.5.1 Once/year	A.10.5.1 MOH/MOA websites	A.10.5.1 Checking	A.10.5.1 NA

and MOA	التابع لوزارة	are posted as			
websites	الصحة	a			
where all		broadcasting			
information,		technique			
studies, news		•			
are					
broadcasted					

## **Axis B: Surveillance**

## Strategic plan

Strategic objective	Activity	Sub-activity	Date (operational plan)	Milestone
B.1 Organization of the work on this axis.	B.1.1 Create a technical working group with TOR	B.1.1.1 Letter from NMCG to nominate the technical group	B.1.1.1 1 month	B.1 1 month
	B.1.2 Assign focal person	B.1.2.1 Letter from NMCG to appoint a focal person (Dr Fatima Mansour)	B.1.2.1 1 month	
B.2 Capacity building of the existing reference laboratory	B.2.1 Check Readiness of existing central to be AMR Reference Lab	B.2.1.1 -Appointment of a subgroup to check readiness of existing central Lab to be the reference Lab for AMR -Suggested subgroup members: -Dr. Adnan -Rula hammoud -Dr. Ahmad Darwish (Laboratory Commission) -Dr. Eyad Qatraji (Laboratory Commission) -Dr. Mazen Dieb (Animal Health Directorate, MOA) -Dr. Shebl Khouri (Public Health Laboratories, MOH) -WHO EMRO specialist	B.2.1.1 Done	B.2 1 year basically (unless B.2.3.2 is not within 1 year)
	B.2.2	B.2.2.1	B.2.2.1 1 month	

	To provide the guidelines of WHO EMRO for AMR Reference Lab to the evaluating subgroup  B.2.3 Ask EMRO to send a specialist to evaluate the central Lab to be an AMR reference Lab and to put a plan of action in order to fill the gaps	Email to Dr. Maha Talaat (Regional Advisor, AMR/IPC, WHO/EMRO) to provide these guidelines B.2.3.1 Letter from MOH to WHO asking for an EMRO specialist.  Letter from WHO Syria to EMRO to ask for the specialist	B.2.3.1 1 month	
		B.2.3.2 Visit of the subgroup and the EMRO specialist to Central Lab and workshop to put the capacity building plan of this lab to become an AMR reference Lab.	B.2.3.2 To be announced by EMRO	
	B.2.4 Provide the Needed equipment, material and expertise for this lab to become the National AMR reference Lab	B.2.4.1 Prepare a budget according to the plan and source of funding for the capacity building of the reference Lab	B.2.4.1 1 year	
B.3 Sentinel surveillance of AMR to report to GLASS in incremental schedules	B.3.1 To designate the hospitals that will be included in this surveillance	B.3.1.1 Put a list of the potential hospitals laboratories (around 8) that could be included -Include the 2 hospitals related to the Ministry of	B.3.1.1 1 month	B.3 3 months

		Defense who already produce automated data  B.3.1.2  Letter from MOH to the included hospitals to ask them to cooperate with the working subgroup created for this sentinel surveillance project	B.3.1.2 2 months	
		B.3.1.3 Letter from MOH to the Ministry of Defense to allow the working subgroup to evaluate the generated data and to ask for the data to be included in the surveillance project	B.3.1.3 1 month	
	B.3.2 Evaluation of the data and the microbiological techniques followed in the labs of Ministry of Defense	B.3.2.1 Audit using GLASS checklist of the only 2 Labs in the country that already generate antibiogram data in order to start surveillance based on the results generated in these 2 labs, if found adequate	B.3.2.1 3 months	
B.4 Capacity building of the Lab in the hospitals listed in the sentinel projects	B.4.1 Appointment of a working subgroup that will be in charge of the capacity building workshops	B.4.1.1 Choosing the members	B.4.1.1 3 months	B.4 1 year

		Appointment of the members	3 months	
	B.4.2 Workshops for training on culture techniques, identification of microorganisms, and AST of organisms isolated in hospital laboratories	B.4.2.1 5-day workshop/ year on this issue	B.4.2.1 4 months	
	B.4.3 QTC (proficiency testing) of these labs after the workshop	B.4.3.1 QTC and follow up	B.4.3.1 5 months	
	B.4.4 2-day workshop for catch up after results of QTC		B.4.4 8 months	
	B.4.5 Equip the labs with needed material that are judged after the 2 <sup>nd</sup> workshop to be ready to provide data according to GLASS checklist	B.4.5.1 Request from NMCG to MOH to provide equipment to these labs	B.4.5.1 1 year	
	B.4.6 Revision of data and cleaning of data before sending to GLASS by an IT technician	B.4.6.1 Data cleaning and preparation to GLASS	B.4.6.1 For the 1 <sup>st</sup> 2 hospitals that are related to the Ministry of Defense 6 months	
B.5 Establish WHONET training	B.5.1 Training of MOH IT employee to use WHONET	B.5.1.1 Send 2 employees from MOH to learn about data entry into GLASS via WHONET	B.5.1.1 6-8 months	B.5 5 years
	B.5.2	B.5.2.1	B.5.2.1	

B.6.1			
MOH sends a mandate to مديرية المشافي that AST/ antibiogram should be done for bacteria isolated from clinical specimens in hospital- and non- hospital- based laboratories	B.6.1.1 مديرية المشافي sends a mandate to all hospitals that AST / antibiogram should be done for bacteria isolated from clinical specimens	B.6.1.1 6 months	B.6 6 months
	B.6.1.2 هيئة المختبرات sends a mandate to all labs that AST / antibiogram should be done for bacteria isolated from clinical specimens	B.6.1.2 6 months	
	B.6.1.3  MOH sends a mandate to hospitals that the cost of antibiograms should be included in their budget	B.6.1.3 6 months	
	B.6.1.4  MOH looks for a source to buy the antibiotic susceptibility testing material in the presence of the current economic embargo	B.6.1.4 3 months	
ar fo cl	ntibiogram should be done or bacteria isolated from inical specimens in ospital- and non- hospital-	htibiogram should be done or bacteria isolated from inical specimens in ospital- and non- hospital- ased laboratories  B.6.1.2  The initial specimens in ospital- and non- hospital- ased laboratories  B.6.1.2  The initial specimens are seed laboratories  B.6.1.2  The initial specimens are seed a mandate to all labs that AST / antibiogram should be done for bacteria isolated from clinical specimens  B.6.1.3  MOH sends a mandate to hospitals that the cost of antibiograms should be included in their budget  B.6.1.4  MOH looks for a source to buy the antibiotic susceptibility testing material in the presence of the current economic	hatibiogram should be done or bacteria isolated from inical specimens in ospital- and non- hospital- ased laboratories  B.6.1.2  B.6.1.2  B.6.1.2  B.6.1.2  AST / antibiogram should be done for bacteria isolated from clinical specimens  B.6.1.2  As a mandate to all labs that AST / antibiogram should be done for bacteria isolated from clinical specimens  B.6.1.3  MOH sends a mandate to hospitals that the cost of antibiograms should be included in their budget  B.6.1.4  MOH looks for a source to buy the antibiotic susceptibility testing material in the presence of the current economic embargo  be a contact in the interval and in the interval and in the interval and in the interval and interval in the presence of the current economic embargo  B.6.1.1  B.6.1.1  B.6.1.2  B.6.1.3  B.6.1.3  B.6.1.3  B.6.1.3  B.6.1.4  AST / antibiogram should be done for bacteria isolated from clinical specimens  B.6.1.2  B.6.1.4  B.6.1.4  AST / antibiogram should be done for bacteria isolated from clinical specimens  B.6.1.4  B.6.1.1  B.6.1.1  B.6.1.1  B.6.1.1  B.6.1.1  B.6.1.1  B.6.1.1  B.6.1.2  B.6.1.3  A months

		هيئة المختبرات updates the prices of clinical	3 months	
		cultures in order to include the cost of the antibiogram		
B.7 Sentinel surveillance of AMR in veterinary labs.	B.7.1 Choose a sentinel group of veterinary clinics/labs for potentially providing AMR surveillance data in animals and plants	B.7.1.1 Evaluate the capacity of these veterinary labs to provide data for the surveillance project and identify the gaps according to GLASS checklist	B.7.1.1 3 months	B.7 3 months
	B.7.2 Invite FAO and OIE and NGO Aghakhan to participate in the surveillance project that requires capacity building of veterinary labs, and providing the needed material for AST	B.7.1.2 Letter from MOA to FAO OIE Aghakhan	B.7.1.2 3 months	
	B.7.3 Letter to Aghakhan that AMR is taken into consideration in the early warning system		B.7.3 1 month	
	B.7.4 Letter to FAO that there is a need for diagnostic material for AMR surveillance in the veterinary and agriculture		B.7.4 1 month	

	fields according to the activity that identifies the gaps needed for the capacity building of the chosen labs.			
	B.7.5 Letter to FAO there is a need for training of personnel in different AMR surveillance issues		B.7.5 1 month	
	B.7.6 Training of the personnel of the veterinary labs that were chosen to be able to provide AMR surveillance data in animals	B.7.6.1 Workshops TOT for lab technicians	B.7.6.1 1 year	
B.8 Establish AMR surveillance in food samples	B.8.1 Put list of priority organisms to be tested along with AST methods		B.8.1 3 months	B.8 3 months
	B.8.2 Send a mandate from MOH to public health labs and to the Directorate of Animal Health to add AST for the priority organisms mentioned above in their food testing protocols		B.8.2 3 months	
B.9	B.9.1		B.9.1 6 months	B.9 5 years

Issue a national AMR surveillance report with stratified results based on local needs of health professionals, researchers, etc. (e.g. nosocomial data, community-acquired data, etc.)	Workshop to put a standard report			
	B.9.2 Start issuing report about surveillance in humans, animals, food and agriculture		B.9.2 Humans: 1 year 1 <sup>st</sup> report from 2 hospitals then yearly, add on other hospitals	
	B.9.3 Publish the report in the following journals: المجلة الطبية مجلة الطب البيطري مجلة الزراعة	B.9.3.1 Get the acceptance of MOH/MOA of sending the report to these journals	B.9.3.1 1 month	
		B.9.3.2 Send the yearly reports to the journals	B.9.3.2 2 years	

## **Operational plan and budget**

Strategic objective	Activity	Sub- activity	Unit	Quantity	Date	Location	Responsibl e entity	Cost	Source of funding	Indicator
B.1 Organizatio n of the work on this axis.	B.1.1 Create a technical working group with TOR	B.1.1.1 Letter from NMCG to nominate the technical group	B.1.1.1 Letter	B.1.1.1 1	B.1.1.1 1 month	B.1.1.1 MOH MOA	B.1.1.1 NMCG	B.1.1.1 None	B.1.1.1	B.1 Technical working group created and focal person appointed
	B.1.2 Assign focal person (Dr Fatima Mansour)	B.1.2.1 Letter from NMCG to appoint a focal person	B.1.2.1 Letter	B.1.2.1 1	B.1.2.1 1 month	B.1.2.1 MOH MOA	B.1.2.1 NMCG	B.1.2.1 None	B.1.2.1	
B.2 Capacity building of the existing reference laboratory	B.2.1 Check Readiness of existing central to be AMR Reference Lab	B.2.1.1  - Appointme nt of a subgroup to check readiness of existing central Lab to be the reference Lab for AMR	B.2.1.1 Letter	B.2.1.1 1	B.2.1.1 Done	B.2.1.1 MOH	B.2.1.1 Surveillanc e axis technical working group	B.2.1.1 None	B.2.1.1	B.2.1, B.2.2, B.2.3 Plan is put to improve the capacity of the existing central lab to fulfill the requiremen ts of the AMR

subgroup members: -Dr. Adnan -Rula hammoud -Dr. Ahmad Darwish (Laboratory Commissio n)	
-Dr. Adnan -Rula hammoud -Dr. Ahmad Darwish (Laboratory Commissio	
Adnan -Rula hammoud -Dr. Ahmad Darwish (Laboratory Commissio	
-Rula hammoud -Dr. Ahmad Darwish (Laboratory Commissio	
hammoud -Dr. Ahmad Darwish (Laboratory Commissio	
-Dr. Ahmad Darwish (Laboratory Commissio	
Ahmad Darwish (Laboratory Commissio	
Darwish (Laboratory Commissio	
(Laboratory Commissio	
Commissio	
-Dr. Eyad	
Qatraji	
(Laboratory	
Commissio	
-Dr. Mazen	
Dieb	
(Animal	
Health   Hea	
Directorate,	
MOA)	
-Dr. Shebl	
Khouri	
(Public	
Health	
Laboratorie	
s, MOH)	

B.2.2 To provide the guidelines of WHO EMRO for AMR Reference Lab to the evaluating subgroup	-WHO EMRO specialist B.2.2.1 Email to Dr. Maha Talaat (Regional Advisor, AMR/IPC, WHO/EM RO) to provide these guidelines	B.2.2.1 Email	B.2.2.1 1	B.2.2.1 1 month	B.2.2.1 WHO office	B.2.2.1 WHO AMR focal person (Dr. Rasmieh Allahham)	B.2.2.1 None	B.2.2.1	
B.2.3 Ask EMRO to send a specialist to evaluate the central Lab to be an AMR reference Lab and to put a plan of action in order to fill the gaps	B.2.3.1 Letter from MOH to WHO asking for an EMRO specialist. Letter from WHO Syria to EMRO to ask for the specialist	B.2.3.1 Letters	B.2.3.1 2	B.2.3.1 1 month	B.2.3.1 MOH WHO Syria	B.2.3.1 Surveillanc e axis technical working group WHO Syria	B.2.3.1 None	B.2.3.1	
	B.2.3.2 Visit of the subgroup	B.2.3.2 Visit	B.2.3.2 1	B.2.3.2	B.2.3.2 Central Lab	B.2.3.2 Surveillanc e axis	B.2.3.2	B.2.3.2 AMR Fund	

		and the EMRO specialist to Central Lab and workshop to put the capacity building plan of this lab to become an AMR reference Lab.	One-day workshop		To be announced by EMRO		technical working group	Fees of EMRO specialist + 2000 USD for the workshop		
	B.2.4 Provide the Needed equipment, material and expertise for this lab to become the National AMR reference Lab	B.2.4.1 Prepare a budget according to the plan and source of funding for the capacity building of the reference Lab	B.2.4.1 Budget And proposal To be sent to potential funders	B.2.4.1 1	B.2.4.1 1 year	B.2.4.1 MOH	B.2.4.1 Reference Lab subgroup members EMRO Specialist	B.2.4.1 Depends on the report of the subgroup	B.2.4.1 MOH WHO Aghakhan	B.2.4 A budget is determined, funding source is identified and the fund is available
B.3 Sentinel surveillanc	B.3.1 To designate	B.3.1.1 Put a list of the	B.3.1.1 List	B.3.1.1 1	B.3.1.1 1 month	B.3.1.1 MOH	B.3.1.1 Surveillanc e axis	B.3.1.1 None	B.3.1.1	B.3.1 List of hospitals

e of AMR to report to GLASS in incremental schedules	the hospitals that will be included in this surveillanc e	potential hospitals laboratories (around 8) that could be included -Include the 2 hospitals related to the Ministry of Defense who already produce automated data					technical working group			that will participate in the sentinel surveillanc e is ready
		B.3.1.2 Letter from MOH to the included hospitals to ask them to cooperate with the working subgroup created for this sentinel	B.3.1.2 Letter	B.3.1.2 1	B.3.1.2 2 months	B.3.1.2 MOH	B.3.1.2 NMCG	B.3.1.2 None	B.3.1.2	

	surveillanc e project								
	B.3.1.3 Letter from MOH to the Ministry of Defense to allow the working subgroup to evaluate the generated data and to ask for the data to be included in the surveillanc e project	B.3.1.3 Letter	B.3.1.3 1	B.3.1.3 1 month	B.3.1.3 MOH	B.3.1.3 NMCG	B.3.1.3 None	B.3.1.3	
B.3.2 Evaluation of the data and the microbiolo gical techniques followed in the labs of Ministry of Defense	B.3.2.1 Audit using GLASS checklist of the only 2 Labs in the country that already generate antibiogra m data in	B.3.2.1 Audit according to GLASS checklist	B.3.2.1 1	B.3.2.1 3 months	B.3.2.1 Ministry of Defense hospitals Labs	B.3.2.1 Working subgroup of this project	B.3.2.1 1,000 USD	B.3.2.1 AMR Fund	B.3.2 Data from the labs of Ministry of Defense reported to GALSS as a starting point from Syria

		order to start surveillanc e based on the results generated in these 2 labs, if found adequate								
B.4 Capacity building of the Lab in the hospitals listed in the sentinel projects	B.4.1 Appointme nt of a working subgroup that will be in charge of the capacity building workshops	B.4.1.1 Choosing the members	B.4.1.1 List	B.4.1.1 1	B.4.1.1 3 months	B.4.1.1 MOH	B.4.1.1 Surveillanc e axis technical working group	B.4.1.1 None	B.4.1.1	B.4 Percentage of labs that were chosen to report to GLASS start reporting to it
		B.4.1.2 Appointme nt of the members	B.4.1.2 Letter	B.4.1.2 1	B.4.1.2 3 months	B.4.1.2 MOH	B.4.1.2 NMCG	B.4.1.2 None	B.4.1.2	
	B.4.2 Workshops for training on culture techniques, identificati on of	B.4.2.1 5-day workshop/ year on this issue	B.4.2.1 Workshop	B.4.2.1 1/year	B.4.2.1 4 months	B.4.2.1 Central Lab	B.4.2.1 Working subgroup for capacity building	B.4.2.1 ????	B.4.2.1 AMR Fund	

microorgan isms, and AST of									
organisms isolated in hospital laboratories									
B.4.3 QTC (proficienc y testing) of these labs after the workshop	B.4.3.1 QTC and follow up	B.4.3.1 2/year/lab	B.4.3.1 Eight the 1st year then 12 2nd year then increase by 4 each year	B.4.3.1 5 months	B.4.3.1 Central Lab	B.4.3.1 Working subgroup for capacity building Central Lab	B.4.3.1 ????	B.4.3.1 AMR Fund	
B.4.4 2-day workshop for catch up after results of QTC		B.4.4 Workshop	B.4.4 1/Lab	B.4.4 8 months	B.4.4 Central Lab	B.4.4 Working subgroup for capacity building	B.4.4 2,500 USD/ workshop	B.4.4 AMR fund	
B.4.5 Equip the labs with needed material that are judged after the 2 <sup>nd</sup> workshop to be ready to provide	B.4.5.1 Request from NMCG to MOH to provide equipment to these labs	B.4.5.1 Lab equipment for microorgan ism identificati on and AST	B.4.5.1 4-5 labs/ year	B.4.5.1 1 year	B.4.5.1 Central Lab	B.4.5.1 MOH WHO	B.4.5.1 ????	B.4.5.1 AMR Fund MOH Fund	

	data according to GLASS checklist									
	B.4.6 Revision of data and cleaning of data before sending to GLASS by an IT technician	B.4.6.1 Data cleaning and preparation to GLASS	B.4.6.1 Data cleaning	B.4.6.1	B.4.6.1 For the 1st 2 hospitals that are related to the Ministry of Defense 6 months	B.4.6.1 MOH	B.4.6.1 MOH IT employee	B.4.6.1 None	B.4.6.1	
B.5 Establish WHONET training	B.5.1 Training of MOH IT employee to use WHONET	B.5.1.1 Send 2 employees from MOH to learn about data entry into GLASS via WHONET	B.5.1.1 Travel to workshop	B.5.1.1 2 employees	B.5.1.1 6-8 months	B.5.1.1 Lebanon or Egypt according to workshop availability	B.5.1.1 MOH	B.5.1.1 3,000 USD /workshop	B.5.1.1 AMR Fund MOH	B.5 None
	B.5.2 General WHONET training for employees of the labs that will send data to GLASS after the	B.5.2.1 16 employees from hospital labs are trained per year	B.5.2.1 3-day workshop	B.5.2.1 1	B.5.2.1 2 years then yearly	B.5.2.1 Central Lab	B.5.2.1 Surveillanc e axis technical working subgroup	B.5.2.1 3,000 USD /year	B.5.2.1 AMR Fund	

B.6 Include antibiotic susceptibili ty testing (AST)/ antibiogra ms into the routine work of medical labs inside and outside	capacity building  B.6.1  MOH sends a mandate to مديرية مديرية hthat AST/ antibiogra m should be done for bacteria isolated from clinical specimens	B.6.1.1 مديرية مديرية المشافي sends a mandate to all hospitals that AST / antibiogra m should be done for bacteria isolated	B.6.1.1 Mandate	B.6.1.1	B.6.1.1 6 months	B.6.1.1 مديرية المشافي	B.6.1.1 NMCG MOH	B.6.1.1 None	B.6.1.1	B.6.1.1 Percentage of hospital labs that generate antibiogra ms for clinical bacteriolog y specimens
	and non- hospital- based laboratories	B.6.1.2 المختبرات sends a mandate to all labs that AST / antibiogra m should be done for	B.6.1.2 Mandate	B.6.1.2 1	B.6.1.2 6 months	B.6.1.2 هيئة المختبرات	B.6.1.2 NMCG MOH	B.6.1.2 None	B.6.1.2	B.6.1.2 Percentage of non-hospital-based labs that generate antibiogra ms for clinical

bacteria								bacteriolog
isolated								у
from								specimens
clinical								
specimens								
B.6.1.3								
MOH								
sends a								
mandate to								
hospitals			B.6.1.3 6 months		B.6.1.3	B.6.1.3 None	B.6.1.3	
that the	B.6.1.3	B.6.1.3		B.6.1.3	NMCG MOH			B.6.1.3
cost of	Mandate	1		МОН				None
antibiogra								
ms should								
be included								
in their								
budget								
B.6.1.4	B.6.1.4							
MOH looks	Task force							
for a source	from MOH				B.6.1.4			
to buy the	for finding				NMCG			
antibiotic	a reliable				MOH			
susceptibili	cost	B.6.1.4	B.6.1.4	B.6.1.4	Surveillanc	B.6.1.4	B.6.1.4	B.6.1.4
ty testing	effective	1	3 months	MOH	e axis	3,000 USD	AMR fund	None
material in	source for				technical	,		
the	material				working			
presence of	needed for				group			
the current	antibiogra				<i>S</i> F			
economic	m							
embargo	generation	7	7		7	7	7	7
B.6.1.5	B.6.1.5	B.6.1.5	B.6.1.5	B.6.1.5	B.6.1.5	B.6.1.5	B.6.1.5	B.6.1.5
I K h l h	Document	1	3 months	D.0.1.3	MOH	None		None

		المختبرات updates the prices of clinical cultures in order to include the cost of the antibiogra m				هيئة المختبرات				
B.7 Sentinel surveillanc e of AMR in veterinary labs.	B.7.1 Choose a sentinel group of veterinary clinics/labs for potentially providing AMR surveillanc e data in animals and plants	B.7.1.1 Evaluate the capacity of these veterinary labs to provide data for the surveillanc e project and identify the gaps according to GLASS checklist	B.7.1.1 List of potential labs	B.7.1.1 1	B.7.1.1 3 months	B.7.1.1 MOA MOH	B.7.1.1 Surveillanc e axis technical working group (that includes a representati ve from the veterinary field)	B.7.1.1 None	B.7.1.1	B.7.1 List of vet. Labs that will participate in the sentinel surveillanc e is available Yes/No.

B.7.2 Invite FAO and OIE and NGO Aghakhan to participate in the surveillanc e project that requires capacity building of veterinary labs, and providing the needed material for AST	B.7.1.2 Letter from MOA to FAO OIE Aghakhan	B.7.1.2 Letters/Me etings with FAO/OIE /Aghakhan representati ves to explain the project of sentinel surveillanc e in vet. labs and the needs for capacity building and material	B.7.1.2 Multiple	B.7.1.2 3 months	B.7.1.2 MOA	B.7.1.2 NMCG MOA	B.7.1.2 None	B.7.1.2	B.7.2 None
B.7.3 Letter to Aghakhan that AMR is taken into considerati on in the early warning system		B.7.3 Letter	B.7.3 1	B.7.3 1 month	B.7.3 MOA	B.7.3 NMCG MOA	B.7.3 None	B.7.3	B.7.3 None

B.7.4 Letter to FAO that there is a need for diagnostic material for AMR surveillanc e in the veterinary and agriculture fields according to the activity that identifies the gaps needed for the capacity building of the chosen labs.	B.7.4 Letter	B.7.4 1	B.7.4 1 month	B.7.4 MOA	B.7.4 NMCG MOA	B.7.4 None	B.7.4 	B.7.4 None
B.7.5 Letter to FAO there is a need for training of personnel	B.7.5 Letter	B.7.5 1	B.7.5 1 month	B.7.5 MOA	B.7.5 NMCG MOA	B.7.5 None	B.7.5	

	in different AMR surveillanc e issues									
	B.7.6 Training of the personnel of the veterinary labs that were chosen to be able to provide AMR surveillanc e data in animals	B.7.6.1 Workshops TOT for lab technicians	B.7.6.1 Workshop	B.7.6.1 2/year	B.7.6.1 1 year	B.7.6.1 MOA	B.7.6.1 Surveillanc e axis technical working group	B.7.6.1 2,500 USD/ workshop	B.7.6.1 AMR fund FAO OIE Aghakhan	B.7.6.1 Percentage of the chosen labs that have sent lab technicians for training
B.8 Establish AMR surveillanc e in food samples	B.8.1 Put list of priority organisms to be tested along with AST methods		B.8.1 List	B.8.1 1	B.8.1 3 months	B.8.1 MOH	B.8.1 Surveillanc e axis technical working group	B.8.1 None	B.8.1	B.8.1 List of priority organisms and correspondi ng AST methods are available

	B.8.2 Send a mandate from MOH to public health labs and to the Directorate of Animal Health to add AST for the priority organisms mentioned above in their food testing protocols	B.8.2 Mandate	B.8.2 2	B.8.2 3 months	B.8.2 MOH	B.8.2 NMCG	B.8.2 None	B.8.2	B.8.2 AMR priority organisms and their AST results are available in Food safety reports
B.9 Issue a national AMR surveillanc e report with stratified results based on local needs of health professiona	B.9.1 Workshop to put a standard report	B.9.1 Workshop	B.9.1 1	B.9.1 6 months	B.9.1 MOH MOA	B.9.1 Surveillanc e axis technical working group Expert	B.9.1 1,500 USD	B.9.1 AMR Fund	B.9 National report is published in journals and on AMR webpages

ls, researchers, etc. (e.g. nosocomial data, community -acquired data, etc.)										
	B.9.2 Start issuing report about surveillanc e in humans, animals, food and agriculture		B.9.2 Yearly reports	B.9.2 3	B.9.2 Humans: 1 year 1 <sup>st</sup> report from 2 hospitals then yearly, add on other hospitals	B.9.2 MOH MOA	B.9.2 NMCG Surveillanc e axis technical working group Expert	B.9.2 30,000 USD/ year	B.9.2 AMR Fund	
	B.9.3  Publish the report in the following journals:  المجلة الطبية مجلة الطبي مجلة الطبي مجلة الزراعة مجلة الزراعة مجلة الزراعة	B.9.3.1 Get the acceptance of MOH/MO A of sending the report to these journals	B.9.3.1 Letter	B.9.3.1 1	B.9.3.1 1 month	B.9.3.1 MOH MOA	B.9.3.1 Surveillanc e axis technical working group	B.9.3.1 None	B.9.3.1	
		B.9.3.2 Send the yearly	B.9.3.2 Report	B.9.3.2 1/year	B.9.3.2 2 years	B.9.3.2 MOH MOA	B.9.3.2 Surveillanc e axis	B.9.3.2 2,000USD/ year	B.9.3.2 AMR Fund	

reports to		technical		
the journals		working		
		group		

## Monitoring and evaluation plan

Strategic objective	Activity	Sub-activity	Indicator	Purpose	Calculation	Frequency	Data source	Method	Baseline
B.1 Organization of the work on this axis.	B.1.1 Create a technical working group with TOR	B.1.1.1 Letter from NMCG to nominate the technical group	B.1 Technical working group created and focal person appointed	B.1 To organize the work of this axis and follow up of the corresponding activities	B.1 Yes/No	B.1 Once/3 months until appointment, then once/5 years	B.1 MOH NMCG	B.1 Checking	B.1 NA
	B.1.2 Assign focal person	B.1.2.1 Letter from NMCG to appoint a focal person (Dr Fatima Mansour)							
B.2 Capacity building of the existing reference laboratory	B.2.1 Check Readiness of existing central to be AMR Reference Lab	B.2.1.1  - Appointment of a subgroup to check readiness of existing central Lab to be the reference Lab for AMR	B.2.1, B.2.2, B.2.3 Plan is put to improve the capacity of the existing central lab to fulfill the requirements of the AMR reference lab	B.2.1, B.2.2, B.2.3 To equip the reference lab to fulfill the functions of the AMR reference lab	B.2.1, B.2.2, B.2.3 Yes/No	B.2.1, B.2.2, B.2.3 Once	B.2.1, B.2.2, B.2.3 Surveillance axis technical working group NMCG	B.2.1, B.2.2, B.2.3 Checking	B.2.1, B.2.2, B.2.3 Reference Lab not ready currently to fulfill this function

	-Suggested				
	-Suggested				
	subgroup				
	members:				
	-Dr. Adnan				
	-Rula				
	hammoud				
	-Dr. Ahmad				
	Darwish				
	(Laboratory				
	Commission				
	)				
	-Dr. Eyad				
	Qatraji				
	(Laboratory				
	Commission				
	)				
	-Dr. Mazen				
	Dieb				
	(Animal				
	Health				
	Directorate,				
	MOA)				
	-Dr. Shebl				
	Khouri				
	(Public				
	Health				
	Laboratories,				
	MOH)				
	-WHO				
	EMRO				
	specialist				
B.2.2	B.2.2.1				

To pro the guideli WHO EMRC AMR Refere	mes of (Regional Advisor, AMR/IPC, WHO/EMR O) to				
Lab to evaluate subgro	ing these				
B.2.3 Ask Ell to send special evaluate central to be a AMR referen Lab an put a p action order to the gar	MRO a ist to te the Lab n    Ce d to lan of in o fill os				
	B.2.3.2 Visit of the subgroup and the EMRO specialist to Central Lab and				

		workshop to put the capacity building plan of this lab to become an AMR reference Lab.							
	B.2.4 Provide the Needed equipment, material and expertise for this lab to become the National AMR reference Lab	B.2.4.1 Prepare a budget according to the plan and source of funding for the capacity building of the reference LAB	B.2.4 A budget is determined, funding source is identified and the fund is available	B.2.4 To actually build the capacity of the current central Lab to become an AMR reference Lab	B.2.4 Yes/No	B.2.4 Once/6 months until everything is secured	B.2.4 Reference Lab	B.2.4 Checking	B.2.4 NA
B.3 Sentinel surveillance of AMR to report to GLASS in incremental schedules	B.3.1 To designate the hospitals that will be included in this surveillance	B.3.1.1 Put a list of the potential hospitals laboratories (around 8) that could be included -Include the 2 hospitals related to the	B.3.1 List of hospitals that will participate in the sentinel surveillance is ready	B.3.1 To ultimately have data reported to GLASS that is microbiologi cally sound ad representativ	B.3.1 Yes/No	B.3.1 Once/3 months until the list is available	B.3.1 Surveillance axis technical working group	B.3.1 Checking	B.3.1 NA

Ministry of	e of the			
Defense who	whole			
already	country			
produce	3			
automated				
data				
B.3.1.2				
Letter from				
MOH to the				
included				
hospitals to				
ask them to				
cooperate				
with the				
working				
subgroup				
created for				
this sentinel				
surveillance				
project				
B.3.1.3				
Letter from				
MOH to the				
Ministry of				
Defense to				
allow the				
working				
subgroup to				
evaluate the				
generated				
data and to				
ask for the				

		data to be included in the surveillance project							
	B.3.2 Evaluation of the data and the microbiologi cal techniques followed in the labs of Ministry of Defense	B.3.2.1 Audit using GLASS checklist of the only 2 Labs in the country that already generate antibiogram data in order to start surveillance based on the results generated in these 2 labs, if found adequate	B.3.2 Data from the labs of Ministry of Defense reported to GALSS as a starting point from Syria	B.3.2 To send the first available data to GLASS	B.3.2 Yes/No	B.3.2 Once/year	B.3.2 Surveillance axis technical working group	B.3.2 Checking	B.3.2 NA
B.4 Capacity building of the Lab in the hospitals listed in the sentinel projects	B.4.1 Appointment of a working subgroup that will be in charge of the capacity	B.4.1.1 Choosing the members	B.4 Percentage of labs that were chosen to report to GLASS start reporting to it	B.4 Standardize the AMR surveillance work and see how many labs will be compliant	B.4 Number of labs actually reporting to GALSS/Tota l number of labs chosen to report	B.4 Once/year	B.4 Surveillance axis technical working group	B.4 Checking	B.4 NA

building workshops		and report to GLASS as required after capacity building	their data to GLASS		
	B.4.1.2 Appointment of the members				
B.4.2 Workshops for training on culture techniques, identification of microorganis ms, and AST of organisms isolated in hospital laboratories	B.4.2.1 5-day workshop/ year on this issue				
B.4.3 QTC (proficiency testing) of these labs after the workshop B.4.4	B.4.3.1 QTC and follow up				

	2-day workshop for catch up after results of QTC					
	B.4.5 Equip the labs with needed material that are judged after the 2 <sup>nd</sup> workshop to be ready to provide data according to GLASS checklist	B.4.5.1 Request from NMCG to MOH to provide equipment to these labs				
	B.4.6 Revision of data and cleaning of data before sending to GLASS by an IT technician	B.4.6.1 Data cleaning and preparation to GLASS				
B.5 Establish WHONET training	B.5.1 Training of MOH IT employee to	B.5.1.1 Send 2 employees from MOH to learn	B.5 None			

	use WHONET	about data entry into GLASS via WHONET							
	B.5.2 General WHONET training for employees of the labs that will send data to GLASS after the capacity building	B.5.2.1 16 employees from hospital labs are trained per year							
B.6 Include antibiotic susceptibility testing (AST)/ antibiograms into the routine work of medical labs inside and outside hospitals	B.6.1  MOH sends a mandate to مديرية المشافي that AST/ antibiogram should be done for bacteria isolated from clinical specimens in hospital- and non- hospital- based laboratories	B.6.1.1 sends a mandate to all hospitals that AST / antibiogram should be done for bacteria isolated from clinical specimens	B.6.1.1 Percentage of hospital labs that generate antibiograms for clinical bacteriology specimens	B.6.1.1 To have a stepwise increase the numbers of labs that produce antibiogram	B.6.1.1  Number of hospital labs that generate antibiograms for routine bacteriology work/Total number of hospital labs	B.6.1.1 Once/year	B.6.1.1 - مديرية المشافي -The hospitals themselves	B.6.1.1 Checking	B.6.1.1 NA

B.6.1.2 هيئة المختبرات sends a mandate to all labs that AST / antibiogram should be done for bacteria isolated from clinical specimens	B.6.1.2 Percentage of non-hospital-based labs that generate antibiograms for clinical bacteriology specimens	B.6.1.2 To increase the number of nonhospital based labs that produce antibiogram	B.6.1.2 Number of non-hospital based medical labs that generate antibiograms for routine bacteriology work/Total number of medical labs outside hospitals	B.6.1.2 Once/year	B.6.1.2 هيئة المختبرات The labs themselves	B.6.1.2 Checking	B.6.1.2 NA
B.6.1.3 MOH sends a mandate to hospitals that the cost of antibiograms should be included in their budget	B.6.1.3 None						
B.6.1.4 MOH looks for a source to buy the antibiotic susceptibility testing material in the presence	B.6.1.4 None						

		of the current economic embargo							
		B.6.1.5  updates the prices of clinical cultures in order to include the cost of the antibiogram	B.6.1.5 None						
B.7 Sentinel surveillance of AMR in veterinary labs.	B.7.1 Choose a sentinel group of veterinary clinics/labs for potentially providing AMR surveillance data in animals and plants	B.7.1.1 Evaluate the capacity of these veterinary labs to provide data for the surveillance project and identify the gaps according to GLASS checklist	B.7.1 List of vet. Labs that will participate in the sentinel surveillance is available Yes/No.	B.7.1 To designate the labs	B.7.1 Enumeration	B.7.1 Once/3 months until the list is available	B.7.1 Surveillance axis technical working group	B.7.1 Checking	B.7.1 NA

B.7.2 Invite FAO and OIE and NGO Aghakhan to participate in the surveillance project that requires capacity building of veterinary labs, and providing the needed material for AST	B.7.1.2 Letter from MOA to FAO OIE Aghakhan	B.7.2 None			
B.7.3 Letter to Aghakhan that AMR is taken into consideratio n in the early warning system		B.7.3 None			
B.7.4 Letter to FAO that there is a need for		B.7.4 None			

diagnostic				
material for				
AMR				
surveillance				
in the				
veterinary				
and				
agriculture				
fields				
according to				
the activity				
that				
identifies the				
gaps needed				
for the				
capacity				
building of				
the chosen				
labs.				
B.7.5				
Letter to				
FAO there is				
a need for				
training of				
personnel in				
different				
AMR				
surveillance				
issues				

	B.7.6 Training of the personnel of the veterinary labs that were chosen to be able to provide AMR surveillance data in animals	B.7.6.1 Workshops TOT for lab technicians	B.7.6.1 Percentage of the chosen labs that have sent lab technicians for training	B.7.6.1 Part of capacity building of these labs	B.7.6.1 Number of labs that have sent technicians to be trained /Number of chosen labs that have sent personnel for training	B.7.6.1 Once/year	B.7.6.1 Attendance sheets of the workshops	B.7.6.1 Checking	B.7.6.1 NA
B.8 Establish AMR surveillance in food samples	B.8.1 Put list of priority organisms to be tested along with AST methods		B.8.1 List of priority organisms and correspondin g AST methods are available	B.8.1 To specify which organisms are to be tested for antimicrobial susceptibility and to which antimicrobial s in food samples	B.8.1 Yes/No	B.8.1 Once/3 months until the list is available.	B.8.1 Surveillance axis technical working group	B.8.1 Checking	B.8.1 NA
	B.8.2 Send a mandate from MOH to public health labs		B.8.2 AMR priority organisms and their AST results	B.8.2 Visualize the actual burden of AMR in priority	B.8.2 Number of priority organisms that have ABX	B.8.2 Once/year	B.8.2 Food safety report	B.8.2 Checking	B.8.2 NA

D.O.	and to the Directorate of Animal Health to add AST for the priority organisms mentioned above in their food testing protocols		are available in food safety reports	organisms in the food chain	susceptibility actually tested/Total number of organisms for which AST is recommende d in food safety as per the defined list				
B.9 Issue a national AMR surveillance report with stratified results based on local needs of health professionals , researchers, etc. (e.g. nosocomial data, community- acquired data, etc.)	B.9.1 Workshop to put a standard report		B.9 National report is published in journals and on AMR webpages	B.9 To improve awareness and stimulate decision makers to contribute to the AMR plan	B.9 Yes/No	B.9 Once/year	B.9 Journals AMR webpage	B.9 Checking	B.9 NA
	B.9.2	1			1				

Start issuing report about surveillance in humans, animals, food and agriculture					
B.9.3 Publish the report in the following journals:  المجلة الطبية مجلة الطب البيطري مجلة الزراعة مجلة الزراعة	B.9.3.1 Get the acceptance of MOH/MOA of sending the report to these journals				
	B.9.3.2 Send the yearly reports to the journals				

## Axis C: IPC

## Strategic plan

Strategic objective	Activity	Sub-activity	Date from operational plan	Milestone
C.1 Organization of the work in this axis	C.1.1 To appoint the members of the technical working group for IPC axis: -Dr. Shebl Khouri (Public Health Laboratories, MOH) - Dr. Fatima Mansour (Public Health Laboratories, MOH) -Dr. Hazar Farouan (Communicable Diseases Directorate, MOH) -Dr. Hani Lahham (Communicable Diseases Directorate, MOH) -Dr. Amer Teebi (Communicable Diseases Directorate, MOH) -Dr. Amer Teebi (Communicable Diseases Directorate, MOH) -Dr. Wahid Rajba Beak (MOHE) -Dr. Majed Bitar (Primary Care/PHCC Directorate, MOH) -Dr Mazen Dieb (Animal Health Directorate, MOA)		C.1.1 1 month	C.1 1 month

	-Dr. Atef Altawel (Environmental Health, MOH) -Dr. Issam Anjek (MOHE)  Put TOR for this group			
	C.1.2 Appoint the focal person (Dr Bashar Haj Ali) through a letter from MOH/MOA		C.1.2 1 month	
C.2 Raise the awareness of officials about the need for national IPC program, committee and working team	C.2.1 Make it a priority of MOH	C.2.1.1 Prepare a report about available local data about nosocomial infections	C.2.1.1 6 months	C.2 8 months
		C.2.1.2 -Meeting with MOH and presentation of data -Requests for the need of a national program with a committee, a focal person, and a special budget	C.2.1.2 8 months	
C.3 Include/Update IPC requirements in accreditation standards of hospitals and in licensing of long-term care facilities (LTCF)	C.3.1.1 Updating IPC in accreditation/licensing manual and make sure it includes essential elements in IPC for hospitals and LTCF		C.3.1.1 1 year	C.3 1 year
	C.3.1.2 Training of accreditation auditors on IPC		C.3.1.2 1 year	

	requirements in the accreditation			
C.4 To recommend establishing IPC programs in Hospitals	C.4.1  Send a letter (تعميم) from to all hospitals for mandatory establishment of an IPC team with at least full time nurse and a part time physician		C.4.1 1 month	C.4 1 month
C.5 Reinforce National IPC Guidelines	C.5.1 Update existing ones	C.5.1.1  Mandate to the technical working group to update them	C.5.1.1 3 months	C.5 8 months
		C.5.1.2 Update the guidelines	C.5.1.2 6 months	
		C.5.1.3  Post the updated guidelines on AMR website	C.5.1.3 8 months	
C.6 To organize IPC professionals education and training	C.6.1 To specify training and prerequisites of IPC officers	C.6.1.1 To put a list of perquisite training and/or qualifications of IPC officers	C.6.1.1 6 months	C.6 1 year
	C.6.2 Workshop for IPC Officers	C.6.2.1 Ask مركز الدراسات الاستراتيجية to give the attendees certificates	C.6.2.1 1 year	
	C.6.3 Training of IPC physicians	C.6.3.1 To specify the qualifications/training needed for a physician to become an IPC physician	C.6.3.1 6 months	

C.7 Offer IPC training for hospital employees in general	C.7.1 General training for nurses	C.7.1.1 TOT Workshop	C.7.1.1 1 year	C.7 1 year
	C.7.2 For newly recruited healthcare workers, physicians, a mandatory yearly IPC training session should be given	to مدراء المشافي that all new employees should have a session of orientation about IPC principles and practice in the hospital	C.7.2.1 1 month	
C.8 IPC training of employees in primary healthcare centers (PHCC)	C.8.1 MOH sends a تعميم to PHCC that there is a need to train employees about IPC		C.8.1 1 month	C.8 1 month
C.9 IPC training of employees in LTCF	C.9.1 MOH asks the Ministry of Social Affairs to recommend training the LTCF personnel on IPC and hygiene practices		C.9.1 2 months	C.9 2 months
C.10 Provide education possibilities for IPC professional as new specialties in IPC	C.10.1 Letter from MOH to MOHE to develop a specialty in IPC		C.10.1 1 month	C.10 1 year
	C.10.2 Workshop for IPC Officers	C.10.2 Ask مركز الدراسات الاستراتيجية to give certificates to the attendees	C.10.2 1 year	

C.11 To establish national process indicators in IPC	C.11.1  -To put a list of these indicators and a plan of action accordingly  -The list will one indicator at a time and the number will increase with time:  1-Hand Hygiene  2-Isolation of XDR organisms  3- the use of PPE		C.11.1 To be started in 1 year	C.11 5 years
	C.11.2 Workshops for TOT for the chosen process indicators (how to audit, calculations, data compilation, etc.)		C.11.2 2 years from time zero	
	C.11.3 Workshops lead by the trained trainers for the team that will collect data about national process indicators in different regions of Syria		C.11.3 2 years and 3 months	
C.12 Research: Surveillance of nosocomial infections	C.12.1 Research project on VAP surveillance	C.12.1.1 Workshop for putting a protocol for the study in hospitals	C.12.1.1 5 years after providing the hospital labs with the necessary equipment	C.12 5 years from time zero depending on each activity/sub-activity
	C.12.2 Research project on CLABSI/ CAUTI surveillance	C.12.2.1 Start auditing	C.12.2.1 5 years from time zero (until building lab capacity has been achieved)	

C.13 Apply IPC practices in animals and agriculture	C.13.1 Reinforce biosafety measures according to OIE guidelines	C.13.1.1 Training workshops about IPC to farmers and veterinarians	C.13.1.1 6 months	C.13 6 months
	C.13.2 Coordination with NGOs	C.13.2.1 Letter from MOA to FAO, OIE, Aghakhan to make AMR and IPC training a priority in their targets	C.13.2.1 2 months	

## **Operational plan and budget**

Strategic objective	Activity	Sub- activity	Unit	Quantity	Date	Location	Responsibl e entity	Cost	Source of funding	Indicator
C.1 Organizatio n of the work in this axis	C.1.1 To appoint the members of the technical working group for IPC axis: -Dr. Shebl Khouri (Public Health Laboratorie s, MOH) - Dr. Fatima Mansour (Public Health Laboratorie s, MOH) - Dr. Fatima Mansour (Public Health Laboratorie s, MOH) -Dr. Hazar Farouan (Communic able		C.1.1 Letter of appointmen t of its members +TOR	C.1.1 1	C.1.1 1 month	C.1.1 MOH MOA	C.1.1 MOH MOHE MOA	C.1.1 None	C.1.1	C.1 Technical working group and focal person appointed

		ı	I			I	1
	Diseases						
I	Directorate,						
1	MOH)						
	-Dr. Hani						
	Lahham						
	(Communic						
	able						
	Diseases						
	Directorate,						
	MOH)						
	-Dr. Amer						
	Teebi						
	(Communic						
	able						
	Diseases						
	Directorate,						
	MOH)						
-	-Dr. Wahid						
I	Rajba Beak						
	(MOHE)						
-	-Dr. Majed						
I	Bitar						
	(Primary						
	Care/PHCC						
I	Directorate,						
1	MOH)						
-	-Dr Mazen						
	Dieb						
	(Animal						
I	Health						
	Directorate,						
	MOA)						

	-Dr. Atef Altawel (Environme ntal Health, MOH) -Dr. Issam Anjek (MOHE)  Put TOR for this group									
	C.1.2 Appoint the focal person (Dr Bashar Haj Ali) through a letter from MOH/MO A		C.1.2 Letter	C.1.2 1	C.1.2 1 month	C.1.2 MOH MOA	C.1.2 MOH MOA	C.1.2 None	C.1.2	
C.2 Raise the awareness of officials about the need for national IPC program, committee	C.2.1 Make it a priority of MOH	C.2.1.1 Prepare a report about available local data about nosocomial infections	C.2.1.1 Report	C.2.1.1 1	C.2.1.1 6 months	C.2.1.1 MOH MOA	C.2.1.1 Dr Bashar Haj Ali (Head of Infection Control Department , Hospital Directorate, MOH)	C.2.1.1 None	C.2.1.1	C.2 Meeting is held where available local data about nosocomial infections is presented

and working team										to officials in MOH
		C.2.1.2 -Meeting with MOH (Minister and Director General Directorate ) and presentatio n of data -Requests for the need of a national program with a committee, a focal person, and a special budget	C.2.1.2 Meeting	C.2.1.2 1	C.2.1.2 8 months	C.2.1.2 MOH	C.2.1.2 Technical working group	C.2.1.2 None	C.2.1.2	
C.3 Include/Up date IPC requiremen ts in accreditatio n standards	C.3.1.1 Updating IPC in accreditatio n/licensing manual and make sure		C.3.1.1 Update the Manual	C.3.1.1 1	C.3.1.1 1 year	C.3.1.1 WHO office	C.3.1.1 WHO/IPC Specialist	C.3.1.1 2,000 USD	C.3.1.1 AMR Fund	C.3.1.1 IPC standards are available in hospital accreditatio

of hospitals and in licensing of long-term care facilities (LTCF)	it includes essential elements in IPC for hospitals and LTCF								n manual checklist and LTCF licensing manual checklist
	C.3.1.2 Training of accreditatio n auditors on IPC requiremen ts in the accreditatio n	C.3.1.2 Training workshop	C.3.1.2 1/year	C.3.1.2 1 year	C.3.1.2 MOH	C.3.1.2 MOH	C.3.1.2 1,500 USD/ workshop	C.3.1.2 AMR Fund	C.3.1.2 None
C.4 To recommend establishing IPC programs in Hospitals	C.4.1 Send a letter (تعميم) from إدارة to all hospitals for mandatory establishme nt of an IPC team with at least 1 full time nurse and a part	C.4.1 تعمیم	C.4.1 1	C.4.1 1 month	C.4.1 مديرية المشافي/ MOH	C.4.1 Dr Bashar Haj Ali (Head of Infection Control Department , Hospital Directorate, MOH)	C.4.1 None	C.4.1	C.4.1 Percentage of hospitals that have IPC team as described

	time physician									
C.5 Reinforce National IPC Guidelines	C.5.1 Update existing ones	C.5.1.1  Mandate to the technical working group to update them	C.5.1.1 Letter	C.5.1.1 1	C.5.1.1 3 months	C.5.1.1 MOH	C.5.1.1 مديرية المشافي/ MOH	C.5.1.1 None	C.5.1.1	C.5 National IPC Guidelines updated and posted on AMR webpage
		C.5.1.2 Update the guidelines	C.5.1.2 Document	C.5.1.2 1	C.5.1.2 6 months	C.5.1.2 MOH Hospitals	C.5.1.2 Technical working group	C.5.1.2 2,000 USD	C.5.1.2 WHO AMR fund	
		C.5.1.3 Post the updated guidelines on AMR website	C.5.1.3 Posting on Website	C.5.1.3 1	C.5.1.3 8 months	C.5.1.3 MOH	C.5.1.3 Technical working group	C.5.1.3 None	C.5.1.3	
C.6 To organize IPC professiona Is education and training	C.6.1 To specify training and prerequisite s of IPC officers	C.6.1.1 To put a list of perquisite training and/or qualificatio ns of IPC officers	C.6.1.1 List	C.6.1.1 1	C.6.1.1 6 months	C.6.1.1 MOH	C.6.1.1 Technical working group	C.6.1.1 None	C.6.1.1	C.6.1.1 Percentage of IPC officers who fulfill the needed requiremen ts/training

	C.6.2 Workshop for IPC Officers	C.6.2.1 Ask مركز الدراسات الاستراتيجية to give the attendees certificates	C.6.2.1 Workshop	C.6.2.1 2/ year first centrally then in all safe governorate s	C.6.2.1 1 year	C.6.2.1 All safe areas in Syria	C.6.2.1 MOH	C.6.2.1 2,500 USD/ workshop	C.6.2.1 AMR fund	C.6.2.1 Percentage of IPC officers that who have attended a local IPC workshop and have a certificate
	C.6.3 Training of IPC physicians	C.6.3.1 To specify the qualificatio ns/training needed for a physician to become an IPC physician	C.6.3.1 List	C.6.3.1 1	C.6.3.1 6 months	C.6.3.1 MOH	C.6.3.1 Technical working group	C.6.3.1 None	C.6.3.1	C.6.3.1 Percentage of IPC physicians who fulfill the needed requiremen ts/training
C.7 Offer IPC training for hospital employees in general	C.7.1 General training for nurses	C.7.1.1 TOT Workshop	C.7.1.1 Workshop	C.7.1.1  1st year: 6/ year  2nd year: 2/year then  2/year each year	C.7.1.1 1 year	C.7.1.1 All safe areas	C.7.1.1 Technical working group MOH	C.7.1.1 4,500 USD/ workshop	C.7.1.1 AMR fund	C.7.1.1 Percentage of safe governorat es that have trained trainers

	C.7.2 For newly recruited healthcare workers, physicians, a mandatory yearly IPC training session should be given	to مدراء المشافي to مدراء المشافي that all new employees should have a session of orientation about IPC principles and practice in the hospital	C.7.2.1 Letter	C.7.2.1 1	C.7.2.1 1 month	C.7.2.1 MOH	C.7.2.1 إدارة المشافي	C.7.2.1 None	C.7.2.1	C.7.2.1 Percentage of newly recruited employees that have attended an IPC orientation session upon employmen t
C.8 IPC training of employees in primary healthcare centers (PHCC)	c.8.1 MOH sends a عنيه to PHCC that there is a need to train employees about IPC		C.8.1 تعمیم	C.8.1 1	C.8.1 1 month	C.8.1 MOH	C.8.1 Technical working group MOH	C.8.1 None	C.8.1	C.8.1 Percentage of PHCC requiring that their employees attend IPC training sessions
C.9 IPC training of employees in LTCF	C.9.1 MOH asks the Ministry of Social Affairs to recommend training the		C.9.1 Letter	C.9.1 1	C.9.1 2 months	C.9.1 MOH	C.9.1 MOH Ministry of Social Affairs	C.9.1 None	C.9.1	C.9.1 Percentage of LTCF requiring that their personnel attend IPC

	LTCF personnel on IPC and hygiene practices									training sessions
C.10 Provide education possibilities for IPC professiona l as new specialties in IPC	C.10.1 Letter from MOH to MOHE to develop a specialty in IPC		C.10.1 Letter	C.10.1 1	C.10.1 1 month	C.10.1 MOH	C.10.1 MOH	C.10.1 None	C.10.1	C.10.1 Number of IPC programs available in higher education institutions
	C.10.2 Workshop for IPC Officers	C.10.2 Ask مركز الدراسات الاستراتيجية to give certificates to the attendees	C.10.2 Workshop	C.10.2 2/ year first centrally then in all safe governorate s	C.10.2 1 year	C.10.2 All safe areas in Syria	C.10.2 MOH	C.10.2 2,500 USD/ workshop	C.10.2 AMR fund	C.10.2 Number of personnel trained
C.11 To establish national process indicators in IPC	C.11.1 -To put a list of these indicators and a plan of action accordingly -The list will one indicator at		C.11.1 List and plan of action	C.11.1 1/year with incremental indications with the years	C.11.1 To be started in 1 year	C.11.1 MOH	C.11.1 Technical working group	C.11.1 1,000 USD/ indicator as fees for data collection and analysis	C.11.1 AMR Fund	C.11.1 Number of national process indicators in IPC that is being followed up each year

a time and the number will increase with time: 1-Hand Hygiene 2-Isolation of XDR organisms 3- the use of PPE									
C.11.2 Workshops for TOT for the chosen process indicators (how to audit, calculation, data compilatio, etc.)	r s	C.11.2 TOT Workshop	C.11.2 Once/ year	C.11.2 2 years from time zero	C.11.2 MOH	C.11.2 Technical working group	C.11.2 2,500 USD/year	C.11.2 AMR Fund	C.11.2 None
C.11.3 Workshops lead by the trained trainers for the team that will collect data		C.11.3 Workshops	C.11.3 5/year	C.11.3 2 years and 3 months	C.11.3 Hospitals in the different safe regions of Syria	C.11.3 Technical working group	C.11.3 5,000 USD/ year	C.11.3 AMR Fund	C.11.3 Percentage of hospitals reporting each included national indicator

	about national process indicators in different regions of Syria									
C.12 Research: Surveillanc e of nosocomial infections	C.12.1 Research project on VAP surveillanc e	C.12.1.1 Workshop for putting a protocol for the study in hospitals	C.12.1.1 Workshop	C.12.1.1 1	C.12.1.1 5 years after providing the hospital labs with the necessary equipment	C.12.1.1 Hospitals	C.12.1.1 Technical working group	C.12.1.1 2,000 USD	C.12.1.1 AMR fund	C.12 Results of the studies are published
	C.12.2 Research project on CLABSI/ CAUTI surveillanc e	C.12.2.1 Start auditing	C.12.2.1 Audit	C.12.2.1 1	C.12.2.1 5 years from time zero (until building lab capacity has been achieved)	C.12.2.1 Hospitals	C.12.2.1 Technical working group	C.12.2.1 4000 USD	C.12.2.1 AMR Fund	
C.13 Apply IPC practices in animals and agriculture	C.13.1 Reinforce biosafety measures according to OIE guidelines	C.13.1.1 Training workshops about IPC to farmers and	C.13.1.1 Workshop	C.13.1.1 5/year	C.13.1.1 6 months	C.13.1.1 Rural areas municipalit ies	C.13.1.1 Technical working group	C.13.1.1 2,500 USD/ workshop/ year	C.13.1.1 AMR fund OIE Aghakhan	C.13.1.1 Number of farmers /per governorat e who attend these

	veterinarian s								training workshops
C.13.2 Coordinatio n with NGOs	C.13.2.1 Letter from MOA to FAO, OIE, Aghakhan to make AMR and IPC training a priority in their targets	C.13.2.1 Letter	C.13.2.1 3	C.13.2.1 2 months	C.13.2.1 MOA	C.13.2.1 Technical working group	C.13.2.1 None	C.13.2.1	C.13.2.1 None

## **Monitoring and evaluation plan**

Strategic objective	Activity	Sub-activity	Indicator	Purpose	Calculation	Frequency	Data source	Method	Baseline
C.1 Organization of the work in this axis	C.1.1 To appoint the members of the technical working group for IPC axis: -Dr. Shebl Khouri (Public Health Laboratories, MOH) - Dr. Fatima Mansour (Public Health Laboratories, MOH) -Dr. Hazar Farouan (Communica ble Diseases Directorate, MOH) -Dr. Hani Lahham		C.1 Technical working group and focal person appointed	C.1 To organize the work in this axis, define responsibiliti es and ensure follow up of task execution	C.1 Yes/No	C.1 Once/5 years	C.1 NMCG	C.1 Checking	C.1 Appointed during stakeholders meeting to put the NAP for Syria. Letter of appointment is pending

(C :				
(Communica				
ble Diseases				
Directorate,				
MOH)				
-Dr. Amer				
Teebi				
(Communica				
ble Diseases				
Directorate,				
MOH)				
-Dr. Wahid				
Rajba Beak				
(MOHE)				
-Dr. Majed				
Bitar				
(Primary				
Care/PHCC				
Directorate,				
MOH)				
-Dr Mazen				
Dieb				
(Animal				
Health				
Directorate,				
MOA)				
-Dr. Atef				
Altawel				
(Environmen				
tal Health,				
MOH)				

	-Dr. Issam Anjek (MOHE) Put TOR for this group								
	C.1.2 Appoint the focal person (Dr Bashar Haj Ali) through a letter from MOH/MOA								
C.2 Raise the awareness of officials about the need for national IPC program, committee and working team	C.2.1 Make it a priority of MOH	C.2.1.1 Prepare a report about available local data about nosocomial infections	C.2 Meeting is held where available local data about nosocomial infections is presented to officials in MOH	C.2 To raise the awareness of officials at MOH in order to get the needed authority and budget to be able to execute the activities of the plan	C.2 Yes/No	C.2 Once	C.2 NMCG	C.2 Checking	C.2 NA
		C.2.1.2 -Meeting with MOH and		•					

		presentation of data -Requests for the need of a national program with a committee, a focal person, and a special budget							
C.3 Include/Upd ate IPC requirements in accreditation standards of hospitals and in licensing of long-term care facilities (LTCF)	C.3.1.1 Updating IPC in accreditation /licensing manual and make sure it includes essential elements in IPC for hospitals and LTCF		C.3.1.1 IPC standards are available in hospital accreditation manual checklist and LTCF licensing manual checklist	C.3.1.1 To make all facilities (hospitals & LTCF) apply IPC principles	C.3.1.1 Yes/No	C.3.1.1 Once/5 years	C.3.1.1 Focal person	C.3.1.1 Checking	C.3.1.1 NA
	C.3.1.2 Training of accreditation auditors on IPC requirements in the accreditation		C.3.1.2 None						

C.4 To recommend establishing IPC programs in Hospitals	C.4.1 Send a letter (متعميم) from إدارة المشافي to all hospitals for mandatory establishmen t of an IPC team with at least 1 full time nurse and a part time physician		C.4.1 Percentage of hospitals that have IPC team as described	C.4.1 Make sure that IPC teams are uniform in all hospitals	C.4.1 Number of hospitals that have IPC team as described/ Total number of hospitals	C.4.1 Once/year	C.4.1 Hospitals	C.4.1 Survey	C.4.1 NA
C.5 Reinforce National IPC Guidelines	C.5.1 Update existing ones	C.5.1.1  Mandate to the technical working group to update them	C.5 National IPC Guidelines updated and posted on AMR webpage	C.5 To make the new guidelines in line with upto-date international recommenda tions based on evidence based medicine	C.5 Yes/No	C.5 Once/ year until available	C.5 AMR Website	C.5 Checking	C.5 NA
		C.5.1.2 Update the guidelines C.5.1.3							

		Post the updated guidelines on AMR website							
C.6 To organize IPC professionals education and training	C.6.1 To specify training and prerequisites of IPC officers	C.6.1.1 To put a list of perquisite training and/or qualification s of IPC officers	C.6.1.1 Percentage of IPC officers who fulfill the needed requirements /training	C.6.1.1 Baseline evaluation of the situation	C.6.1.1  Number of IPC officers who fulfill the needed requirements /Total number of IPC officers checked	C.6.1.1 Once/year	C.6.1.1 Hospitals	C.6.1.1 Survey Accreditatio n audit	C.6.1.1 NA
	C.6.2 Workshop for IPC Officers	C.6.2.1 Ask مركز الدراسات الاستراتيجية to give the attendees certificates	C.6.2.1 Percentage of IPC officers that who have attended a local IPC workshop and have a certificate	C.6.2.1 To make sure that the IPC officers are well trained according to the up-to-date IPC principles & practices	C.6.2.1 Number of IPC officers that who have attended a local IPC workshop and have a certificate/ Total number of IPC officers	C.6.2.1 Once/year	C.6.2.1 Hospitals	C.6.2.1 Survey Accreditatio n audit	C.6.2.1 NA
	C.6.3 Training of IPC physicians	C.6.3.1 To specify the qualification	C.6.3.1 Percentage of IPC physicians	C.6.3.1 To make sure that physicians	C.6.3.1 Number of IPC physicians	C.6.3.1 Once/2 years	C.6.3.1 Hospitals	C.6.3.1 Survey	C.6.3.1 NA

		s/training needed for a physician to become an IPC physician	who fulfill the needed requirements /training	are in charge of IPC are properly trained and well qualified	who fulfill the needed requirements / Total number of IPC physicians				
C.7 Offer IPC training for hospital employees in general	C.7.1 General training for nurses	C.7.1.1 TOT Workshop	C.7.1.1 Percentage of safe governorates that have trained trainers	C.7.1.1 To have trained professionals help spreading the know how in IPC throughout the whole safe areas of the country	C.7.1.1 Number of safe governorates that have trained trainers/ Total number of governorates	C.7.1.1 Once/year	C.7.1.1 Attendance sheets of these workshops	C.7.1.1 Checking	C.7.1.1 NA
	C.7.2 For newly recruited healthcare workers, physicians, a mandatory yearly IPC training session should be given	to hospital directors that all new employees should have a session of orientation about IPC principles and practice	C.7.2.1 Percentage of newly recruited employees that have attended an IPC orientation session upon employment	C.7.2.1 To have a start up education and not to miss those who have been employed after the yearly general	C.7.2.1  Number of newly recruited employees that have attended an IPC orientation session upon employment/ Total number of	C.7.2.1 Yearly	C.7.2.1 Hospitals	C.7.2.1 Survey Accreditatio n audit	C.7.2.1 NA

		in the hospital		employees session	newly recruited employees				
C.8 IPC training of employees in primary healthcare centers (PHCC)	C.8.1 MOH sends a read to PHCC that there is a need to train employees about IPC		C.8.1 Percentage of PHCC requiring that their employees attend IPC training sessions	C.8.1 To have employees in primary care sensitized and apply IPC practices	C.8.1 Number of PHCC requiring that their employees attend IPC training sessions /Total number of PHCC	C.8.1 Once/year	C.8.1 PHCC	C.8.1 Survey	C.8.1 NA
C.9 IPC training of employees in LTCF	C.9.1 MOH asks the Ministry of Social Affairs to recommend training the LTCF personnel on IPC and hygiene practices		C.9.1 Percentage of LTCF requiring that their personnel attend IPC training sessions	C.9.1 To have employees in LTCF sensitized and apply IPC practices	C.9.1 Number of LTCF requiring that their personnel attend IPC training sessions /Total number of LTCF	C.9.1 Once/year	C.9.1 LTCF	C.9.1 Survey	C.9.1 NA
C.10 Provide education possibilities for IPC professional	C.10.1 Letter from MOH to MOHE to develop a		C.10.1 Number of IPC programs available in	C.10.1 To provide local education opportunities	C.10.1 Number	C.10.1 Yearly	C.10.1 Higher education institutions	C.10.1 Survey	C.10.1 NA

as new specialties in IPC	specialty in IPC		higher education institutions	to Higher education students who like to have a profession in this field					
	C.10.2 Workshop for IPC Officers	C.10.2 Ask مركز الدراسات الاستراتيجية to give certificates to the attendees	C.10.2 Number of personnel trained	C.10.2 To make sure that the IPC officers are well trained according to the up-to-date IPC principles & practices	C.10.2 Yes/No	C.10.2 Once/year	C.10.2 Hospitals	C.10.2 Survey	C.10.2 NA
C.11 To establish national process indicators in IPC	C.11.1 -To put a list of these indicators and a plan of action accordingly -The list will one indicator at a time and the number will increase with time: 1-Hand Hygiene		C.11.1 Number of national process indicators in IPC that is being followed up each year	C.11.1 To have a follow up at the national level on the key performance indicators in IPC	C.11.1 Number	C.11.1 Once/year	C.11.1 MOH	C.11.1 Checking	C.11.1 NA

2-Isolation of XDR organisms 3- the use of PPE							
C.11.2 Workshops for TOT for the chosen process indicators (how to audit, calculations, data compilation, etc.)	C.11.2 None						
C.11.3 Workshops lead by the trained trainers for the team that will collect data about national process indicators in different regions of Syria	C.11.3 Percentage of hospitals reporting each included national indicator	C.11.3 To increase gradually the number of hospitals that report data on national indicators and have the results representative of the country	C.11.3 Number of hospitals reporting each included national indicator /Total number of hospitals	C.11.3 Once/year	C.11.3 MOH Hospitals	C.11.3 Checking	C.11.3 NA

C.12 Research: Surveillance of nosocomial infections	C.12.1 Research project on VAP surveillance	C.12.1.1 Workshop for putting a protocol for the study in hospitals	C.12 Results are published	C.12 Follow up on the efficacy and application of IPC principles in hospitals	C.12 Yes/No	C.12 Once	C.12 Investigators MOH Technical working group	C.12 Checking	C.12 NA
	C.12.2 Research project on CLABSI/ CAUTI surveillance	C.12.2.1 Start auditing							
C.13 Apply IPC practices in animals and agriculture	C.13.1 Reinforce biosafety measures according to OIE guidelines	C.13.1.1 Training workshops about IPC to farmers and veterinarians	C.13.1.1 Number of farmers /per governorate who attend these training workshops	C.13.1.1 To sensitize and improve awareness of farmers about biosafety including IPC practices	C.13.1.1 Number	C.13.1.1 Once/year	C.13.1.1 Attendance sheets of these workshops	C.13.1.1 Checking	C.13.1.1 NA
	C.13.2 Coordination with NGOs	C.13.2.1 Letter from MOA to FAO, OIE, Aghakhan to make AMR and IPC	C.13.2.1 None						

training a			
priority in			
their targets			

## **Axis D: Antibiotic Use**

## Strategic plan

Strategic objective	Activity	Sub-activity	Date from operational plan	Milestone
D.1 Organization of the tasks in this axis	D.1.1 Establishing the technical working group and focal person	D.1.1.1 Nomination Document	D.1.1.1 1 month	D.1 1 month
		D.1.1.2 Putting TOR	D.1.1.2 1 month	
		D.1.1.3 Assigning Focal Person (Dr Hani Laham)	D.1.1.3 1 month	
D.2 To check the QC of generic and copy antibiotics that are licensed in the country	D.2.1 To apply bio- equivalence studies to antimicrobials	D.2.1.1 Letter from NMCG to the Directorate of Drugs to consider ABX to be a priority in the bioequivalence project that is being prepared at the Directorate of Drugs	D.2.1.1 1 month	D.2 1 year
	D.2.2 To check the type of chemical and biological analysis of medicines (ABX) that is a prerequisite for their licensing before introduction in the market	D.2.2.1 MOH recommends a meeting between the drug licensing authority and a technical subgroup to review the tested ABX in 2018, the licensed and the refused	D.2.2.1 2 months	

ones and the results of		
testing		
D.2.2.2		
The technical subgroup		
reviews the results of QC of	D.2.2.2	
the chemical and biological	3 months	
analysis of ABX during		
2018		
D.2.2.3		
The technical subgroup that		
audited the pre-licensing	D 2 2 2	
testing submits a report to	D.2.2.3	
the NMCG to evaluate the	4 months	
situation and put a final plan		
of the pre-licensing testing		
D.2.2.4		
To ask authorities that		
licensing of ABX to be done	D 0 0 4	
according to a formula that	D.2.2.4	
includes QC to be taken into	2 months	
consideration, not only the		
price		
D.2.2.5		
The Axis D technical		
working group puts a		
checklist for the		
characteristics of ABX	D.2.2.5	
formulations to be accepted	3 months	
in the market. This list		
should apply to both		
imported and locally		
manufactured ABX		

	D.2.3 الرقابة الدوانية control on transport of ABX	D.2.3.1 MOH and MOA ask الرقابة الدوائية to check on transport conditions of ABX	D.2.3.1 2 months	
	D.2.4 Program of pharmacovigilance for ABX (post marketing surveillance)	D.2.4.1  NMCG asks معاون الوزير لشؤون الصيدلة والدواء to put ABX as top priority for pharmacovigilance	D.2.4.1 3 months	
		D.2.4.2 Workshop for physicians and pharmacists on how to report ineffectiveness or side effect of medicines	D.2.4.2 1 year	
	D.2.5 Essential medicine list to be updated		D.2.5 3 months	
	D.2.6 Mandate from MOH that each hospital has its essential medicine list and ABX as part of it		D.2.6 1 month	
D.3 Regulate dispensing of ABX in pharmacies	D.3.1 Reinforce the law that prevents dispensing of ABX in pharmacies without a physician's prescription	D.3.1.1 List of high-priority ABX to be dispensed only with a prescription is put (Priority ABX)	D.3.1.1 3 months	D.3 4 months
		D.3.1.2 MOH sends a تعميم	D.3.1.2 1 month	

	to pharmacies to priority ABX on controlled medic	their list of	
		D.3.2 4 months	
sends a بيم to NGOs i dispense	ealth care authority in order not to high priority ABX edical prescription	D.3.3 1 month	
قابة الدوائية 29/T	D.3.4.1 Presence of High ABX In the checklist o على الصيدليات ولجنة ABX in its round	D.3.4.1	
D.3.5 MOH,		D.3.5 Every 2-3 months	

	Order of Physicians, and هيئة الرقابة على الصيدليات will call/visit  D.3.6  Prescription is of 2 papers		D.3.6 1 month	
	including a carbon-copy  D.3.7  from MOH to The Social Affairs that antibiotic dispensing is forbidden in dispensaries without a physician's prescription who abides by the written guidelines		D.3.7 1 month	
D.4 Reinforce the code of ethics for pharmaceutical companies in issues related to marketing ABX	D.4.1 Apply the code of ethics to ABX marketing	D.4.1.1 Meeting to put the Syrian code of ethics for advertisement and incentives	D.4.1.1 3 months	D.4 4 months
		D.4.1.2  Mandate from MOH to pharmaceutical companies to abide by the code of ethics	D.4.1.2 4 months	
D.5 Preparation for antimicrobial stewardship programs (ASP) by preparation of	D.5.1 Establish guidelines and protocols for ID management	D.5.1.1 Guidelines/ABX protocols for: -Uncomplicated UTI	D.5.1.1 6 months	D.5 2 years

local ID treatment guidelines for hospitals		-Upper respiratory tract infection -Diarrhea in children -Surgical Antibiotic Prophylaxis		
		D.5.1.2  MOH sends a تعمیم to hospitals to recommend use these protocols as a guide for patient management	D.5.1.2 1 year	
		D.5.1.3  To include these protocols in الرعاية الصحية	D.5.1.3 1 year 3 months	
	D.5.2 Broadcasting these guidelines to all scientific societies	D.5.2.1 Order of Physicians sends a mandate to include these guidelines among the lectures and activities of the meetings of the scientific societies in the country (Ex: UTI guidelines in Family Medicine, Internal Medicine, Urology Societies Meetings)	D.5.2.1 2 years	
	D.5.3 To make the management proposed by these guidelines easily accessible to practitioners during daily work	D.5.3.1  Make posters with protocol algorithm as easy reference of the management proposed by these guidelines	D.5.3.1 1 year	
		D.5.3.2	D.5.3.2	

		Post these posters in different healthcare facilities and on AMR website	1 year 2 months	
	D.5.4 Guidelines related to ABX in hospitals other than UTI, CAP and acute diarrhea: Ex: Establish judicious surgical ABX prophylaxis practices and use	D.5.4.1  مديرية المشافي المؤسسات  الاستشفانية المستشفيات  sends a circular to hospitals  to implement proper use of  surgical ABX prophylaxis  through the established  guidelines	D.5.4.1 1 year	
D.6 Regulate the use of high-risk ABX as an early antimicrobial stewardship activity	D.6.1 Establish a list and guidelines for using critically important ABX in hospital setting including carbapenems, colistin, vancomycin, teicoplanin, linezolid, tigecycline, etc.		D.6.1 6 months	D.6 1 year
	D.6.2  asks hospitals to give lectures about these guidelines/ protocols to different departments (critical care, internal medicine, pediatrics, obstetrics, oncology, etc.)		D.6.2 1 year	
	D.6.3 مديرية المشافي		D.6.3 1 year	

D.7 Regulate ABX use in agriculture and veterinary fields	asks hospitals to restrict the use of high-risk ABX based on written guidelines  D.7.1  متعبد from MOA to forbids dispensing ABX without prescription from a specialist in the field (Veterinarian)		D.7.1 1 month	D.7 1 year
	D.7.2 Put a list of ABX that should not be used in animals and agriculture because they can be used in humans		D.7.2 6 months	
	D.7.3 Communicate this list with FAO, OIE, and Aghakhan to include awareness about the implication of using these ABX in animals and agriculture in their activities (workshops and awareness sessions)	D.7.3 Letter from Axis D technical working group To FAO, OIE, Agahkhan	D.7.3 6 months	
	D.7.4  متعميد from MOA that forbids the purchase of these ABX for veterinary and agriculture use		D.7.4 8 months	
	D.7.5	D.7.5.1 Plan for control visits to veterinary clinics, veterinary pharmacies and farms,	D.7.5.1 1 year	

To organize control visits from audit committee at MOA to veterinary clinics,	especially to those who are selling these products		
pharmacies and farms to			
check whether these			
products are being sold			
	D.7.6		
D.7.6	send a تعميم to farmers and	D.7.6	
To reinforce the law of	slaughter houses about	3 months	
Withdrawal period	withdrawal period and	5 monus	
	reinforce its control		

## **Operational plan and budget**

Strategic objective	Activity	Sub- activity	Unit	Quantity	Date	Location	Responsibl e entity	Cost	Source of funding	Indicator
D.1 Organizatio n of the tasks in this axis	D.1.1 Establishin g the technical working group and focal person	D.1.1.1 Nomination Document	D.1.1.1 Nominatio n letter with the list of members	D.1.1.1 1	D.1.1.1 1 month	D.1.1.1 MOH MOA	D.1.1.1 NMCG	D.1.1.1 None	D.1.1.1	D.1 technical working group appointed with clear TOR and focal person appointed
		D.1.1.2 Putting TOR	D.1.1.2 List of TOR inside nomination letter	D.1.1.2 1	D.1.1.2 1 month	D.1.1.2 MOH MOA	D.1.1.2 NMCG	D.1.1.2 None	D.1.1.2	
		D.1.1.3 Assigning Focal Person (Dr Hani laham)	D.1.1.3 Nominatio n letter	D.1.1.3 1	D.1.1.3 1 month	D.1.1.3 MOH MOA	D.1.1.3 NMCG	D.1.1.3 None	D.1.1.3	
D.2 To check the QC of generic and copy antibiotics that are	D.2.1 To apply bio-equivalence studies to antimicrobi als	D.2.1.1 Letter from NMCG to the Directorate of Drugs to consider	D.2.1.1 Letter	D.2.1.1 1	D.2.1.1 1 month	D.2.1.1 MOH	D.2.1.1 NMCG	D.2.1.1 None	D.2.1.1	D.2.1 Percentage of locally available ABX that are tested for

licensed in the country		ABX to be a priority in the bioequivale nce project that is being prepared at the Directorate of Drugs								bioequivale nce
	D.2.2 To check the type of chemical and biological analysis of medicines (ABX) that is a prerequisite for their licensing before introductio n in the market	D.2.2.1 MOH recommend s a meeting between the drug licensing authority and a technical subgroup to review the tested ABX in 2018, the licensed and the refused ones and the results of testing	D.2.2.1 Letter from MOH to directorate of drug pre- licensing testing	D.2.2.1 1	D.2.2.1 2 months	D.2.2.1 MOH Drug pre- licensing office	D.2.2.1 NMCG	D.2.2.1 None	D.2.2.1	D.2.2.1 to D.2.2.4 Report about QC of ABX that is being carried in the Drug directorate is sent to NMCG and a consequent plan is issued
		D.2.2.2	D.2.2.2	D.2.2.2	D.2.2.2	D.2.2.2	D.2.2.2	D.2.2.2	D.2.2.2	

te su re re con	The rechnical subgroup reviews the results of QC of the chemical and piological analysis of ABX during 2018	Visit and research	1	3 months	Drug pre- licensing office	Technical subgroup	3,000 USD	AMR Fund	
To the sum of the sum	D.2.2.3 The rechnical subgroup that audited the pre-icensing resting submits a report to the NMCG recovaluate the situation and put a final plan of the pre-icensing resting resting resting resting resting resting resting resting resting	D.2.2.3 Report	D.2.2.3 1	D.2.2.3 4 months	D.2.2.3 MOH	D.2.2.3 Technical subgroup	D.2.2.3 Included above	D.2.2.3 AMR Fund	

D.2.2.4 To ask authorities that licensing of ABX to be done according to a formula that includes QC to be taken into considerati on, not only the price	D.2.2.4 Document	D.2.2.4 1	D.2.2.4 2 months	D.2.2.4 MOH	D.2.2.4 Axis D technical working group	D.2.2.4 None	D.2.2.4	
D.2.2.5 The Axis D technical working group puts a checklist for the characterist ics of ABX formulation s to be accepted in the market. This list	D.2.2.5 List	D.2.2.5 1	D.2.2.5 3 months	D.2.2.5 MOH	D.2.2.5 Axis D technical working group	D.2.2.5 None	D.2.2.5	D.2.2.5 Checklist for QC of ABX is available and sent to the drug licensing committee

	should apply to both imported and locally manufactur ed ABX								
D.2.3 الرقابة الدوائية control on transport of ABX	D.2.3.1 MOH and MOA ask الرقابة to check on transport conditions of ABX	D.2.3.1 Document	D.2.3.1 1	D.2.3.1 2 months	D.2.3.1 MOH MOA	D.2.3.1 NMCG	D.2.3.1 None	D.2.3.1	D.2.3 Document with audit results on conditions of transport of ABX is available on a yearly basis
D.2.4 Program of pharmacovi gilance for ABX (post marketing surveillanc e)	D.2.4.1  NMCG  asks  معاون الوزير  لشؤون  الصيدلة  والدواء  والدواء  to put ABX  as top  priority for  pharmacovi  gilance	D.2.4.1 Document	D.2.4.1 1	D.2.4.1 3 months	D.2.4.1 MOH MOA	D.2.4.1 NMCG	D.2.4.1 None	D.2.4.1	D.2.4 Number of ABX formulation s that are being reviewed in the pharmacovi gilance project at MOH
	D.2.4.2 Workshop for	D.2.4.2 Workshops	D.2.4.2 2	D.2.4.2 1 year	D.2.4.2	D.2.4.2	D.2.4.2 2,500 USD/ workshop	D.2.4.2 Pharmacovi gilance	

		physicians and pharmacists on how to report ineffectiven ess or side effect of				وزارة شؤون الصيدلة و الدواء	وزارة شؤون الصيدلة و الدواء		project from وزارة شؤون الصيدلة و الدواء	
		medicines								
	D.2.5 Essential medicine list to be updated		D.2.5 List	D.2.5 1	D.2.5 3 months	D.2.5 MOH	D.2.5 Axis D technical working group	D.2.5 None	D.2.5	D.2.5 Essential medicine list at drug office at MOH is updated Yes/No
	D.2.6 Mandate from MOH that each hospital has its essential medicine list and ABX as part of it		D.2.6 Mandate	D.2.6 1	D.2.6 1 month	D.2.6 Hospitals	D.2.6 MOH	D.2.6 None	D.2.6	D.2.6 None
D.3 Regulate dispensing of ABX in pharmacies	D.3.1 Reinforce the law that prevents dispensing	D.3.1.1 List of high- priority	D.3.1.1 List	D.3.1.1	D.3.1.1 3 months	D.3.1.1 MOH	D.3.1.1 Axis D technical working group	D.3.1.1 None	D.3.1.1	D.3.1.1 List is put Yes/No

of ABX in pharmacies without a physician's prescription	ABX to be dispensed only with a prescription is put (Priority ABX)								
	D.3.1.2 MOH sends a عمر to pharmacies to include priority ABX on their list of controlled medicines	D.3.1.2 تعميم	D.3.1.2 1	D.3.1.2 1 month	D.3.1.2 Pharmacies	D.3.1.2 MOH	D.3.1.2 None	D.3.1.2	D.3.1.2 Percentage of pharmacies that include priority ABX on their list of controlled medicines
D.3.2 Send a that forbids dispensing ABX that are included in the high priority list without prescription		D.3.2 Ta3mim	D.3.2 1	D.3.2 4 months	D.3.2 MOH	D.3.2 Dr Razan Salota (Pharmaceu tical Affairs, MOH) Axis D technical working group	D.3.2 None	D.3.2	D.3.2 Percentage of pharmacies abiding the regulations of not dispensing high priority ABX without prescriptions

D.3.3  Primary health care authority sends a منعيد to NGOs i order not t dispense high priority ABX without medical prescription	n O	D.3.3 Ta3mim	D.3.3	D.3.3 1 month	D.3.3 Primary Health Care authorities	D.3.3 Axis D technical working group Primary Health Care authorities	D.3.3 None	D.3.3	D.3.3 Percentage of NGO medical care centers that do not dispense ABX without a prescriptio n
D.3.4 هيئة الرقابة على على الصيدليات الصيدليات الرقابة الرقابة الدوانية 29/T will have ABX in its round	checklist of هیئة الرقابة علی	D.3.4.1 Document	D.3.4.1 1	D.3.4.1 1 month	D.3.4.1 MOH	D.3.4.1 هيئة الرقابة على الصيدليات ولجنة الرقابة الدوانية	D.3.4.1 None	D.3.4.1	D.3.4  Presence of High priority ABX in the checklist of غيئة الرقابة الصيدليات على Yes/No
D.3.5 MOH, Order of Physicians and	,	D.3.5 Call/Visit	D.3.5 1	D.3.5 Every 2-3 months	D.3.5 MOH, Order of Physicians	D.3.5 MOH, Order of Physicians, and	D.3.5 None	D.3.5	D.3.5 Percentage of pharmacies that are

هيئة الرقابة على الصيدليات will call/visit					هيئة الرقابة على الصيدليات			being visited by هيئة الرقابة على على الصيدليات
D.3.6 Prescriptio n is of 2 papers including a carbon- copy	D.3.6 Document	D.3.6 1	D.3.6 1 month	D.3.6 MOH, Order of Physicians	D.3.6 MOH, Order of Physicians	D.3.6 None	D.3.6	D.3.6 None
from MOH to The Social Affairs that antibiotic dispensing is forbidden in dispensarie s without a physician's prescription who abides by the written guidelines	D.3.7 تعمیم	D.3.7 1	D.3.7 1 month	D.3.7 MOH	D.3.7 Axis D technical working group MOH	D.3.7 None	D.3.7	D.3.7 Percentage of dispensarie s abiding the regulations regarding ABX dispensing

D.4 Reinforce the code of ethics for pharmaceut ical companies in issues related to marketing ABX	D.4.1 Apply the code of ethics to ABX marketing	D.4.1.1 Meeting to put the Syrian code of ethics for advertisem ent and incentives	D.4.1.1 Meeting	D.4.1.1 1	D.4.1.1 3 months	D.4.1.1 WHO	D.4.1.1 Axis D technical working group WHO	D.4.1.1 2,500 USD	D.4.1.1 AMR Fund	D.4.1.1 None
		D.4.1.2 Mandate from MOH to pharmaceut ical companies to abide by the code of ethics	D.4.1.2 Mandate	D.4.1.2 1	D.4.1.2 4 months	D.4.1.2 MOH	D.4.1.2 NMCG MOH	D.4.1.2 None	D.4.1.2	D.4.1.2 None
D.5 Preparation for antimicrobi al stewardship programs (ASP) by preparation of local ID treatment	D.5.1 Establish guidelines and protocols for ID manageme nt	D.5.1.1 Guidelines/ ABX protocols for: - Uncomplic ated UTI -Upper respiratory	D.5.1.1 Guidelines	D.5.1.1 4	D.5.1.1 6 months	D.5.1.1 MOH	D.5.1.1 Technical subgroup for writing these guidelines	D.5.1.1 1,000 USD/ guidelines set Total 4,000 USD	D.5.1.1 AMR fund	D.5.1 Guidelines published on official AMR webpage

guidelines for hospitals		tract infection -Diarrhea in children -Surgical Antibiotic Prophylaxis								
		D.5.1.2 MOH sends a عمر to hospitals to recommend use these protocols as a guide for patient manageme nt	D.5.1.2 تعمیم	D.5.1.2 1	D.5.1.2 1 year	D.5.1.2 MOH	D.5.1.2 NMCG	D.5.1.2 None	D.5.1.2	
		D.5.1.3  To include these protocols in الرعاية	D.5.1.3 تعميم موجه لمديرية الرعاية الصحية	D.5.1.3 1	D.5.1.3 1 year 3 months	D.5.1.3 MOH	D.5.1.3 NMCG gets approval of the Minister of Health	D.5.1.3 None	D.5.1.3	
	D.5.2 Broadcastin g these guidelines to all	D.5.2.1 Order of Physicians sends a mandate to include	D.5.2.1 Mandate from Order of physicians	D.5.2.1 Number of scientific societies	D.5.2.1 2 years	D.5.2.1 Conference s	D.5.2.1 Axis D technical working group	D.5.2.1 None	D.5.2.1	D.5.2.1 Percentage of scientific societies that have included

scientific societies	these guidelines among the lectures and activities of the meetings of the scientific societies in the country (Ex: UTI guidelines in Family Medicine, Internal Medicine, Urology Societies	to scientific societies				Order of physicians			these guidelines in one or more of their meetings.
D.5.3 To make the manageme nt proposed by these guidelines easily accessible to practitioner	Meetings) D.5.3.1 Make posters with protocol algorithm as easy reference of the manageme nt proposed	D.5.3.1 Posters	D.5.3.1 ?/Guideline s	D.5.3.1 1 year	D.5.3.1 MOH WHO	D.5.3.1 WHO	D.5.3.1 5,000 USD	D.5.3.1 AMR Fund	D.5.3.1 Percentage of health care facilities having these posters held in their premises

	s during	by these								
		guidelines								
	daily work	D.5.3.2				<del> </del>				
		Post these posters in different healthcare facilities and on AMR website	D.5.3.2 Posters	D.5.3.2 ?/Guideline s	D.5.3.2 1 year 2 months	D.5.3.2 Healthcare facilities	D.5.3.2 MOH	D.5.3.2 None	D.5.3.2	D.5.3.2 None
	D.5.4 Guidelines related to ABX in hospitals other than UTI, CAP and acute diarrhea: Ex: Establish judicious surgical ABX prophylaxis practices and use	D.5.4.1 مديرية المشافي\ المؤسسات الاستشفائية\ المستشفائية\ المستشفائية\ sends a circular to hospitals to implement proper use of surgical ABX prophylaxis through the established guidelines	D.5.4.1 Circular	D.5.4.1 1	D.5.4.1 1 year	D.5.4.1 مديرية المشافي	D.5.4.1 NMCG	D.5.4.1 None	D.5.4.1	D.5.4.1 None
D.6	D.6.1		D.6.1	D.6.1			D.6.1			D.6.1
Regulate	Establish a		Writing	To be	D.6.1	D.6.1	Dr.Wahid	D.6.1	D.6.1	Guidelines
the use of	list and		guidelines/	assigned	6 months	MOH	Rajb Beak	5,000 USD	AMR Fund	are issued,
high-risk	guidelines		protocols	later			(MOHE) +			published

ABX as an early antimicrobi al stewardship activity	for using critically important ABX in hospital setting including carbapene ms, colistin, vancomyci n, teicoplanin, linezolid, tigecycline, etc.	for ABX use				Another ID physician + ICU Haytham Bshara			in journals, posted on AMR website
	D.6.2 مديرية مديرية asks hospitals to give lectures about these guidelines/ protocols to different department s (critical care, internal medicine,	D.6.2 Document	D.6.2 1	D.6.2 1 year	D.6.2 مديرية المشافي	D.6.2 NMCG	D.6.2 None	D.6.2	D.6.2 Number of lectures given per year related to these guidelines

	pediatrics, obstetrics, oncology, etc.)  D.6.3 مديرية مديرية asks hospitals to restrict the use of high- risk ABX based on written guidelines	D.6.3 Document	D.6.3 1	D.6.3 1 year	D.6.3 مديرية المشافي	D.6.3 NMCG	D.6.3 None	D.6.3	D.6.3 Percentage of hospitals restricting the use of high-risk ABX
D.7 Regulate ABX use in agriculture and veterinary fields	D.7.1  השביב from  MOA to  forbids  dispensing  ABX  without  prescription  from a  specialist in  the field  (Veterinari  an)	D.7.1 تعمیم	D.7.1 1	D.7.1 1 month	D.7.1 MOA	D.7.1 MOA	D.7.1 None	D.7.1	D.7.1 None
	D.7.2 Put a list of ABX that should not	D.7.2 List	D.7.2 1	D.7.2 6 months	D.7.2 MOA	D.7.2 اللجنة الفنية للدواء البيطري	D.7.2 None	D.7.2	D.7.2 None

be used in animals and agriculture because they can be used in humans						Axis D technical working group			
D.7.3 Communicate this list with FAO, OIE, and Aghakhan to include awareness about the implication of using these ABX in animals and agriculture in their activities (workshop and awareness sessions)	D.7.3 Letter from Axis D technical working group To FAO, OIE, Agahkhan	D.7.3 Letters	D.7.3 3	D.7.3 6 months	D.7.3 MOA	D.7.3 اللجنة الفنية الدواء البيطري Axis D technical working group	D.7.3 None	D.7.3	D.7.3 Number of awareness sessions about ABX use in agriculture and veterinary fields/year
D.7.4 متعمیم from		D.7.4 تعمیم	D.7.4 1	D.7.4 8 months	D.7.4 MOA	D.7.4 Axis D technical	D.7.4 None	D.7.4	D.7.4 None

MOA the forbids purchase these AE for veterinar and agriculturuse	of X y					working group اللجنة الفنية للدواء البيطري			
D.7.5 To organize control visits fro audit committe at MOA veterinar clinics, pharmac and farm to check whether these products are being sold	visits to veterinary clinics, veterinary pharmacies and farms, especially to those who are selling these products	D.7.5.1 Plan	D.7.5.1 1	D.7.5.1 1 year	D.7.5.1 MOA	D.7.5.1 Axis D technical working اللجنة group الفنية للدواء	D.7.5.1 None	D.7.5.1	D.7.5.1 None
D.7.6 To reinforce the law of	tarmers and	D.7.6 تعمیم	D.7.6 1	D.7.6 3 months	D.7.6 MOA	D.7.6 MOA	D.7.6 None	D.7.6	D.7.6 None

Withdrawal	houses				
period	about				
	withdrawal				
	period and				
	reinforce				
	its control				

## **Monitoring and evaluation plan**

Strategic objective	Activity	Sub-activity	Indicator	Purpose	Calculation	Frequency	Data source	Method	Baseline
D.1 Organization of the tasks in this axis	D.1.1 Establishing the technical working group and focal person	D.1.1.1 Nomination Document	D.1 technical working group appointed with clear TOR and focal person appointed	D.1 To organize the work, define responsibiliti es, and ensure follow up and task execution	D.1 Yes/No	D.1 Once/3 months until nomination document is issued	D.1 MOH	D.1 Checking	D.1 NA
		D.1.1.2							
		Putting TOR							
		D.1.1.3							
		Assigning							
		Focal							
		Person (Dr							
		Hani Laham)							
D.2 To check the QC of generic and copy antibiotics that are licensed in the country	D.2.1 To apply bio-equivalence studies to antimicrobial s	D.2.1.1 Letter from NMCG to the Directorate of Drugs to consider ABX to be a priority in the bioequivalen	D.2.1 Percentage of locally available ABX that are tested for bioequivalen ce	D.2.1 To make sure that the available generics in the market have been compared by bioequivalen ce studies to	D.2.1 Number of generic ABX that are subject to chemical and biological bioequivalen ce testing/all generic ABX available in	D.2.1 Once/ 6 months	D.2.1 Drug office in MOH	D.2.1 Visit and checking	D.2.1 Unknown

	ce project that is being prepared at the Directorate of Drugs		the original brands	the Syrian market				
D.2.2 To check the type of chemical and biological analysis of medicines (ABX) that is a prerequisite for their licensing before introduction in the market	D.2.2.1 MOH recommends a meeting between the drug licensing authority and a technical subgroup to review the tested ABX in 2018, the licensed and the refused ones and the results of testing	D.2.2.1 to D.2.2.4 Report about QC of ABX that is being carried in the Drug directorate is sent to NMCG and a consequent plan is issued	D.2.2.1 to D.2.2.4 To evaluate the process of generic and copy ABX acceptance into the market	D.2.2.1 to D.2.2.4 Meeting	D.2.2.1 to D.2.2.4 6 months	D.2.2.1 to D.2.2.4 MOH Technical subgroup	D.2.2.1 to D.2.2.4 Meeting	D.2.2.1 to D.2.2.4 NA
	D.2.2.2 The technical subgroup reviews the results of QC of the chemical and							

biological	
analysis of	
ABX during	
2018	
D.2.2.3	
The	
technical	
subgroup	
that audited	
the pre-	
licensing	
testing	
submits a	
report to the	
NMCG to	
evaluate the	
situation and	
put a final	
plan of the	
pre-licensing	
testing	
D.2.2.4	
To ask	
authorities	
that	
licensing of	
ABX to be	
done	
according to	
a formula	
that includes	

	QC to be taken into consideratio n, not only the price  D.2.2.5  The Axis D technical working group puts a checklist for the characteristic s of ABX formulations to be accepted in the market. This list should apply to both imported and	D.2.2.5 Checklist for QC of ABX is available and sent to drug licensing committee	D.2.2.5 To make sure that ABX released in the Syrian market are of an acceptable quality regarding bioequivalen ce and bioactivity	D.2.2.5 Yes/No	D.2.2.5 Once/3 months until the list is ready and sent to licensing authorities	D.2.2.5 Licensing authorities Axis D technical working group	D.2.2.5 Checking	D.2.2.5 NA
	imported and locally manufacture d ABX		bioactivity					
D.2.3 الرقابة الدوانية control on transport of ABX	D.2.3.1  MOH and  MOA  ask الرقابة to  check on  transport	D.2.3 Document with audit results on conditions of transport of ABX is	D.2.3 To make sure that ABX are transported under the	D.2.3 Yes/No	D.2.3 ??	D.2.3 الرقابة الدوانية	D.2.3 Checking	D.2.3 NA

	conditions of	available on	proper					
	ABX	a yearly	conditions					
		basis						
D.2.4 Program of pharmacovig ilance for ABX (post marketing surveillance)	D.2.4.1  NMCG asks معاون الوزير لشؤون الصيدلة والدواء to put ABX as top priority for pharmacovig ilance	D.2.4 Number of ABX formulations that are being reviewed in the pharmacovig ilance project at MOH	D.2.4 To do post marketing follow up of the quality of antimicrobial s	D.2.4 Number	D.2.4 Once/year	D.2.4 Pharmacovig ilence project at MOH	D.2.4 Checking	D.2.4 NA
	D.2.4.2 Workshop for physicians and pharmacists on how to report ineffectivene ss or side effect of medicines							
D.2.5 Essential medicine list to be updated		D.2.5 Essential medicine list at drug office at	D.2.5 To make sure that all needed ABX are available	D.2.5 Yes/No	D.2.5 Once/6 months until updated	D.2.5 Drug office at MOH	D.2.5 Checking	D.2.5 Not updated

			MOH is updated Yes/No						
	D.2.6 Mandate from MOH that each hospital has its essential medicine list and ABX as part of it		D.2.6 None						
D.3 Regulate dispensing of ABX in pharmacies	D.3.1 Reinforce the law that prevents dispensing of ABX in pharmacies without a physician's prescription	D.3.1.1 List of high-priority ABX to be dispensed only with a prescription is put (Priority ABX)	D.3.1.1 List is put Yes/No	D.3.1.1 To be able to restrict the most important ABX	D.3.1.1 Yes/No	D.3.1.1 Every 3 months until the list is put	D.3.1.1 MOH	D.3.1.1 Checking	D.3.1.1 NA
		D.3.1.2 MOH sends a ta3mim to pharmacies to include priority ABX on their list of controlled medicines	D.3.1.2 Percentage of pharmacies that include priority ABX on their list of controlled medicines	D.3.1.2 To follow up on this issue	D.3.1.2 Number of pharmacies that include priority ABX on their list of controlled medicines/T otal number	D.3.1.2 Once/ 3 months	D.3.1.2 MOH	D.3.1.2 Checking	D.3.1.2 NA

D.3.2 Send a  تعمین  that forbids dispensing ABX that are included in the high priority list without prescription	D.3.2 Percentage of pharmacies abiding the regulations of not dispensing high priority ABX without prescriptions	D.3.2 To increase the number of pharmacies that do not dispense high priority ABX without a medical prescription	of pharmacies D.3.2 Number of pharmacies abiding the regulations of not dispensing high priority ABX without prescriptions /Total number of pharmacies	D.3.2 Once/ 3 months	D.3.2 Pharmacies	D.3.2 Visits	D.3.2 NA
D.3.3 Primary health care authority sends a تعميم to NGOs in order not to dispense high priority ABX without medical prescription	D.3.3 Percentage of NGO medical care centers that do not dispense ABX without a prescription	D.3.3 To prevent erratic dispensing of ABX outside the official pharmacies by NGOs	D.3.3 Number of NGO medical care centers that do not dispense ABX without a prescription /Total number of NGO medical care centers	D.3.3 Once/3 months	D.3.3 NGO medical care centers	D.3.3 Visits	D.3.3 NA

D.3.4 هيئة الرقابة على الصيدليات ولجنة الرقابة الدوائية 29/T will have ABX in its round	D.3.4.1 Presence of High priority ABX in the checklist of auit Mair auit Mai	D.3.4  Presence of High priority ABX in the checklist of هينة الرقابة على الصيدليات على الصيدليات Yes/No	D.3.4 To have هيئة الرقابة على الصيدليات ولجنة الرقابة control the dispensing of high priority ABX in pharmacies	D.3.4 Number	D.3.4 Once/ 6 months	D.3.4 هيئة الرقابة على الصيدليات ولجنة الرقابة	D.3.4 Checking	D.3.4 NA
D.3.5 MOH, Order of Physicians, and هيئة الرقابة على الصيدليات will call/visit		D.3.5 Percentage of pharmacies that are being visited by auis illustration	D.3.5 To control the dispensing of high priority ABX in pharmacies	D.3.5 Number of pharmacies controlled/ Total number of pharmacies	D.3.5 Every 2-3 months	D.3.5 هيئة الرقابة على الصيدليات	D.3.5 Visits/calls	D.3.5 NA
D.3.6 Prescription is of 2 papers including a carbon-copy		D.3.6 None						
from MOH to The Social Affairs that antibiotic dispensing is		D.3.7 Percentage of dispensaries abiding the regulations regarding	D.3.7 To avoid dispensing ABX by dispensary without prescription	D.3.7 Number of dispensaries abiding the regulations regarding	D.3.7 Once	D.3.7 MOH	D.3.7 Checking	D.3.7 NA

	forbidden in dispensaries without a physician's prescription who abides by the written guidelines		ABX dispensing	while banning them in pharmacies without prescription	ABX dispensing/ Total number of dispensaries				
D.4 Reinforce the code of ethics for pharmaceuti cal companies in issues related to marketing ABX	D.4.1 Apply the code of ethics to ABX marketing	D.4.1.1 Meeting to put the Syrian code of ethics for advertisemen t and incentives	D.4.1.1 None						
		D.4.1.2 Mandate from MOH to pharmaceuti cal companies to abide by the code of ethics	D.4.1.2 None						
D.5 Preparation for	D.5.1 Establish guidelines	D.5.1.1 Guidelines/A BX	D.5.1 Guidelines published on	D.5.1 To make sure	D.5.1 Yes/No	D.5.1 To check every 6	D.5.1 AMR website	D.5.1 Checking	D.5.1 NA

antimicrobial	and	protocols	official	guidelines		months until			
stewardship	protocols for	for:	AMR	were		posted			
programs	ÎD	-	webpage	prepared and					
(ASP) by	management	Uncomplicat	1 0	made public					
preparation		ed UTI		1					
of local ID		-Upper							
treatment		respiratory							
guidelines		tract							
for hospitals		infection							
1		-Diarrhea in							
		children							
		-Surgical							
		Antibiotic							
		Prophylaxis							
		D.5.1.2							
		MOH sends							
		a تعميم to							
		hospitals to							
		recommend							
		use these							
		protocols as							
		a guide for							
		patient							
		management							
		D.5.1.3							
		To include							
		these							
		protocols in							
		الرعاية الصحية							
	D.5.2	D.5.2.1	D.5.2.1	D.5.2.1	D.5.2.1	D.5.2.1	D.5.2.1	D.5.2.1	D.5.2.1
	Broadcasting	Order of	Percentage	To increase	Number of	Once/year	Scientific	Survey	NA
	these	Physicians	of scientific	awareness of	scientific	Office/ year	societies	Survey	11/1

guidelines to	sends a	societies that	professionals	societies that				
all scientific	mandate to	have	a about these	have				
societies	include these	included	guidelines	included				
	guidelines	these	and direct	these				
	among the	guidelines in	their practice	guidelines in				
	lectures and	one or more	accordingly	one or more				
	activities of	of their		of their				
	the meetings	meetings.		meetings				
	of the			/Total				
	scientific			number of				
	societies in			scientific				
	the country			societies.				
	(Ex: UTI							
	guidelines in							
	Family							
	Medicine,							
	Internal							
	Medicine,							
	Urology							
	Societies							
	Meetings)							
D.5.3	D.5.3.1			D.5.3.1				
To make the	Make	D.5.3.1	D.5.3.1	Number of				
management	posters with	Percentage	Increase the	health care				
proposed by	protocol	of health	visibility of	facilities				
these	algorithm as	care	these	having these	D.5.3.1	D.5.3.1	D.5.3.1	D.5.3.1
guidelines	easy	facilities	protocols	posters held	Once/ 3	Health care	Visits	NA
easily	reference of	having these	and make	in their	months	facilities	v 15115	11/1
accessible to	the	posters held	them easily	premises				
practitioners	management	in their	accessible to	/Total				
during daily	proposed by	premises	practitioners	number of				
work	proposed by			health care				

		these guidelines			facilities that were checked				
		D.5.3.2 Post these posters in different healthcare facilities and on AMR website	D.5.3.2 None						
	D.5.4 Guidelines related to ABX in hospitals other than UTI, CAP and acute diarrhea: Ex: Establish judicious surgical ABX prophylaxis practices and use	D.5.4.1 المؤسسات المؤسسات الموسسات الاستشفائية الاستشفائية sends a circular to hospitals to implement proper use of surgical ABX prophylaxis through the established guidelines	D.5.4.1 None						
D.6 Regulate the use of high-risk ABX as an early	D.6.1 Establish a list and guidelines for using		D.6.1 Guidelines are issued, published in journals,	D.6.1 Guidelines should be prepared to pave the way	D.6.1 Yes/No	D.6.1 Once/ 3 months until they are	D.6.1 AMR website	D.6.1 Checking	D.6.1 NA

antimicrobial stewardship activity	critically important ABX in hospital setting including carbapenems , colistin, vancomycin, teicoplanin, linezolid, tigecycline, etc.	posted on AMR website	for antimicrobial stewardship in hospitals		published on the website	Local medical journals		
	asks hospitals to give lectures about these guidelines/ protocols to different departments (critical care, internal medicine, pediatrics, obstetrics, oncology, etc.)	D.6.2  Number of lectures given per year related to these guidelines	D.6.2 To spread the knowledge about these guidelines and encourage practitioners to read them and use them in daily work	D.6.2 Number	D.6.2 Once/year	D.6.2 Hospitals	D.6.2 Checking	D.6.2 NA
	D.6.3	D.6.3	D.6.3	D.6.3	D.6.3	D.6.3	D.6.3	D.6.3

	asks hospitals to restrict the use of high- risk ABX based on written guidelines	Percentage of hospitals restricting the use of high-risk ABX	To limit the use of these ABX to professionals who have received training about the related guidelines and to ID specialists to avoid overuse and emergence of further resistance	Number of hospitals restricting the use of high-risk ABX/ Total number of hospitals	Once/year	Hospitals	Survey to hospitals	NA
D.7 Regulate ABX use in agriculture and veterinary fields	D.7.1 تعميم from MOA to forbids dispensing ABX without prescription from a specialist in the field (Veterinarian )	D.7.1 None						
	D.7.2	D.7.2 None						

s b a a b c	Put a list of ABX that should not be used in animals and agriculture because they can be used in humans								
i a a a i i a a a a i i a a a a a s	D.7.3 Communicat e this list with FAO, OIE, and Aghakhan to include awareness about the implication of using these ABX in animals and agriculture in their activities (workshops and awareness sessions)	D.7.3 Letter from Axis D technical working group To FAO, OIE, Agahkhan	D.7.3 Number of awareness sessions about ABX use in agriculture and veterinary fields/year	D.7.3 Improve awareness of veterinarians and farmers about the misuse of ABX in their fields as well as its impact on humans	D.7.3 Number	D.7.3 Once/year	D.7.3 MOA FAO	D.7.3 Checking	D.7.3 Partially available through OIE biosafety awareness plan
	D.7.4 تعمید		D.7.4 None						

MOA forbids Purchase of these ABX for veterinary and agriculture use					
D.7.5 To organize control visits from audit committee at MOA to veterinary clinics, pharmacies and farms to check whether these products are being sold	D.7.5.1 Plan for control visits to veterinary clinics, veterinary pharmacies and farms, especially to those who are selling these products	D.7.5.1 None			
D.7.6 To reinforce the law of Withdrawal period	D.7.6 Send a منعن to farmers and slaughter houses about withdrawal period and	D.7.6 None			

reinfo	force its			
contro	trol			

## **References**

- Al-Assil B, Mahfoud M, Hamzeh AR. First report on class 1 integrons and Trimethoprim-resistance genes from dfrA group in uropathogenic E. coli (UPEC) from the Aleppo area in Syria. Mob Genet Elem 2013;3:e25204.
- Alheib O, Al Kayali R, Abajy MY. Prevalence of plasmid-mediated quinolone resistance (PMQR) determinants among extended spectrum beta-lactamases (ESBL)-producing isolates of Escherichia coli and Klebsiella pneumoniae in Aleppo, Syria. Arch Clin Infect Dis 2015;10:, doi:http://dx.doi.org/10.5812/ archcid.20631.
- Fouad FM, Sparrow A, Tarakji A, et al. Health workers and the weaponisation of health care in Syria: a preliminary inquiry for The Lancet—American University of Beirut Commission on Syria. Lancet 2017;6736:1–11.
- Mahfoud M, Al Najjar M, Hamzeh AR. Multidrug resistance in Pseudomonas aeruginosa isolated from nosocomial respiratory and urinary infections in Aleppo, Syria. J Infect Dev Ctries 2015;9:210–3.
- Syrian Center for Policy Research. Population status & analysis. Syrian Center for Policy Research SCPR; 2018.
- Tabana Y, Dahham S, Al-Hindi B, Al-Akkad A, Khadeer Ahamed MB.
   Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) among medical staff in three Syrian provinces. Middle East J Sci Res 2015;23:1756–64.
- WHO. HeRAMS Syria: Snapshot for Public Hospitals. 2018.